

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 September 2002 (19.09.2002)

PCT

(10) International Publication Number
WO 02/072084 A2

(51) International Patent Classification⁷: **A61K 31/19**,
31/215, A61P 5/38, 5/44, 5/46, C07C 62/32, 62/34, 62/38,
69/753, 235/40, C07D 295/13, 295/182, 213/40, C07J
7/00, 9/00, 51/00, A61K 31/16, 31/165, 31/4402, 31/5375,
31/5685, 31/57

(21) International Application Number: PCT/GB02/01060

(22) International Filing Date: 7 March 2002 (07.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0105772.8 8 March 2001 (08.03.2001) GB

(71) Applicant (for all designated States except US): **STERIX LIMITED** [GB/GB]; Magdalen Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **POTTER, Barry,**

Victor, Lloyd [GB/GB]; c/o Sterix Limited, Magdalen Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA (GB). **PUROHIT, Atul** [GB/GB]; c/o Sterix Limited, Magdalen Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA (GB). **REED, Michael, John** [GB/GB]; c/o Sterix Limited, Magdalen Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA (GB). **VICKER, Nigel** [GB/GB]; c/o Sterix Limited, Magdalen Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA (GB).


(74) Agents: **ALCOCK, David** et al.; D Young & Co, 21 New Fetter Lane, London EC4A 1DA (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: USE

Effect of different compounds on the conversion E \Rightarrow F, in rat liver, 11 β -HSD



Graph 4, the effect of different inhibitors on the conversion E to F in rat liver, 11 β -HSD type 1.

(57) Abstract: The present invention provides use of a compound in the manufacture of a medicament to inhibit 11 β -HSD activity, wherein the compound is selected from glycyrrhetic acid derivatives, progesterone and progesterone derivatives.



(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

USE

The present invention relates to use of compounds to inhibit 11β -hydroxysteroid dehydrogenase (11β -HSD).

5

Introduction

The role of glucocorticoids

Glucocorticoids are synthesised in the adrenal cortex from cholesterol. The principle
10 glucocorticoid in the human body is cortisol, this hormone is synthesised and secreted in
response to the adrenocorticotrophic hormone (ACTH) from the pituitary gland in a
circadian, episodic manner, but the secretion of this hormone can also be stimulated by
stress, exercise and infection. Cortisol circulates mainly bound to transcortin (cortisol
binding protein) or albumin and only a small fraction is free (5-10%) for biological
15 processes [1].

Cortisol has a wide range of physiological effects, including regulation of carbohydrate,
protein and lipid metabolism, regulation of normal growth and development, influence on
cognitive function, resistance to stress and mineralocorticoid activity. Cortisol works in
20 the opposite direction compared to insulin meaning a stimulation of hepatic
gluconeogenesis, inhibition of peripheral glucose uptake and increased blood glucose
concentration. Glucocorticoids are also essential in the regulation of the immune
response. When circulating at higher concentrations glucocorticoids are
immunosuppressive and are used pharmacologically as anti-inflammatory agents.

25

Glucocorticoids like other steroid hormones are lipophilic and penetrate the cell
membrane freely. Cortisol binds, primarily, to the intracellular glucocorticoid receptor
(GR) that then acts as a transcription factor to induce the expression of glucocorticoid
responsive genes, and as a result of that protein synthesis.

30

The role of the 11β -HSD enzyme


The conversion of cortisol (F) to its inactive metabolite cortisone (E) by 11β -HSD was
first described in the 1950's, however it was not until later that the biological importance
35 for this conversion was suggested [2]. In 1983 Krozowski et al. showed that the

mineralocorticoid receptor (MR) has equal binding affinities for glucocorticoids and mineralocorticoids [3]. Because the circulating concentration of cortisol is a 100 times higher than that of aldosterone and during times of stress or high activity even more, it was not clear how the MR remained mineralocorticoid specific and was not constantly occupied by glucocorticoids. Earlier Ulick et al. had described the hypertensive condition known as, "apparent mineralocorticoid excess" (AME), and observed that whilst secretion of aldosterone from the adrenals was in fact low the peripheral metabolism of cortisol was disrupted. These discoveries lead to the suggestion of a protective role for the enzymes. By converting cortisol to cortisone in mineralocorticoid dependent tissues 11 β -HSD enzymes protects the MR from occupation by glucocorticoids and allows it to be mineralocorticoid specific. Aldosterone itself is protected from the enzyme by the presence of an aldehyde group at the C-18 position.

Congenital defects in the 11 β -HSD enzyme results in over occupation of the MR by cortisol and hypertensive and hypokalemic symptoms seen in AME.

Localisation of the 11 β -HSD showed that the enzyme and its activity is highly present in the MR dependent tissues, kidney and parotid. However in tissues where the MR is not mineralocorticoid specific and is normally occupied by glucocorticoids, 11 β -HSD is not present in these tissues, for example in the heart and hippocampus [5]. This research also showed that inhibition of 11 β -HSD caused a loss of the aldosterone specificity of the MR in these mineralocorticoid dependent tissues.

It has been shown that two iso-enzymes of 11 β -HSD exist. Both are members of the *short chain alcohol dehydrogenase* (SCAD) superfamily which have been widely conserved throughout evolution. 11 β -HSD type 2 acts as a dehydrogenase to convert the secondary alcohol group at the C-11 position of cortisol to a secondary ketone, so producing the less active metabolite cortisone. 11 β -HSD type 1 is thought to act mainly in vivo as a reductase, that is in the opposite direction to type 2 [6] [see below]. 11 β -HSD type 1 and type 2 have only a 30% amino acid homology.



11 β-HSD enzyme activity

The intracellular activity of cortisol is dependent on the concentration of glucocorticoids and can be modified and independently controlled without involving the overall secretion and synthesis of the hormone.

The role of 11 β-HSD Type 1

The direction of 11 β-HSD type 1 reaction in vivo is generally accepted to be opposite to the dehydrogenation of type 2. In vivo homozygous mice with a disrupted type 1 gene are unable to convert cortisone to cortisol, giving further evidence for the reductive activity of the enzyme [7]. 11 β-HSD type 1 is expressed in many key glucocorticoid regulated tissues like the liver, pituitary, gonad, brain, adipose and adrenals, however, the function of the enzyme in many of these tissues is poorly understood [8].

The concentration of cortisone in the body is higher than that of cortisol, cortisone also binds poorly to binding globulins, making cortisone many times more biologically available. Although cortisol is secreted by the adrenal cortex, there is a growing amount of evidence that the intracellular conversion of E to F may be an important mechanism in regulating the action of glucocorticoids [9].

It may be that 11 β-HSD type 1 allows certain tissues to convert cortisone to cortisol to increase local glucocorticoid activity and potentiate adaptive response and counteracting the type 2 activity that could result in a fall in active glucocorticoids [10]. Potentiation of the stress response would be especially important in the brain and high levels of 11 β-HSD type 1 are found around the hippocampus, further proving the role of the enzyme. 11 β-HSD type 1 also seems to play an important role in hepatocyte maturation [8]. Another emerging role of the 11 β-HSD type 1 enzyme is in the detoxification process of

many non-steroidal carbonyl compounds, reduction of the carbonyl group of many toxic compounds is a common way to increase solubility and therefore increase their excretion. The 11 β -HSD type 1 enzyme has recently been shown to be active in lung tissue [11]. Type 1 activity is not seen until after birth, therefore mothers who smoke
5 during pregnancy expose their children to the harmful effects of tobacco before the child is able to metabolically detoxify this compound.

The role of 11 β -HSD Type 2

10 As already stated earlier the 11 β -HSD type 2 converts cortisol to cortisone, thus protecting the MR in many key regulatory tissues of the body. The importance of protecting the MR from occupation by glucocorticoids is seen in patients with AME or liquorice intoxication. Defects or inactivity of the type 2 enzyme results in hypertensive syndromes and research has shown that patients with an hypertensive syndrome have
15 an increased urinary excretion ratio of cortisol : cortisone. This along with a reported increase in the half life of radiolabelled cortisol suggests a reduction of 11 β -HSD type 2 activity [12].

Rationale for the development of 11 β -HSD inhibitors

20 As said earlier cortisol opposes the action of insulin meaning a stimulation of hepatic gluconeogenesis, inhibition of peripheral glucose uptake and increased blood glucose concentration. The effects of cortisol appear to be enhanced in patients suffering from glucose intolerance or diabetes mellitus. Inhibition of the enzyme 11 β -HSD type 1
25 would increase glucose uptake and inhibit hepatic gluconeogenesis, giving a reduction in circulatory glucose levels. The development of a potent 11 β -HSD type 1 inhibitor could therefore have considerable therapeutic potential for conditions associated with elevated blood glucose levels.

30 An excess in glucocorticoids can result in neuronal dysfunctions and also impair cognitive functions. A specific 11 β -HSD type 1 inhibitor might be of some importance by reducing neuronal dysfunctions and the loss of cognitive functions associated with ageing, by blocking the conversion of cortisone to cortisol.

35 Glucocorticoids also have an important role in regulating part of the immune response


[13]. Glucocorticoids can suppress the production of cytokines and regulate the receptor levels. They are also involved in determining whether T-helper (Th) lymphocytes progress into either Th1 or Th2 phenotype. These two different types of Th cells secrete a different profile of cytokines, Th2 is predominant in a glucocorticoid environment. By inhibiting 11 β -HSD type 1, Th1 cytokine response would be favoured. It is also possible to inhibit 11 β -HSD type 2, thus by inhibiting the inactivation of cortisol, it may be possible to potentiate the anti-inflammatory effects of glucocorticoids.

WO 97/07789 teaches the provision of a compound for inhibiting HSD Type 1 in vivo. Only one compound, carbenoxolone, is disclosed in this document. There is therefore a desire for additional compounds which may be used for the inhibition of HSD.

The present invention alleviates the problems of the prior art.

Aspects of the invention are defined in the appended claims.

In one aspect the present invention provides use of a compound in the manufacture of a medicament to inhibit 11 β -HSD activity wherein the compound is a compound or (a salt thereof) of the formula



wherein R₃ and R₄ together define one or more rings, wherein the compound is substituted with one or more groups which are or which contain -OH or =O, with the proviso that the compound is other than carbenoxolone and glycyrrhetic acid.

In one aspect the present invention provides use of a compound in the manufacture of a medicament to inhibit 11 β -HSD activity, wherein the compound is selected from glycyrrhetic acid derivatives, progesterone and progesterone derivatives.

In one aspect the present invention provides use of a compound of the present invention in the manufacture of a medicament for use in the therapy of a condition or disease associated with 11 β -HSD.

In one aspect the present invention provides use of a compound of the present invention in the manufacture of a medicament for use in the therapy of a condition or disease associated adverse 11 β -HSD levels.

- 5 In one aspect the present invention provides a method of inhibiting 11 β -HSD in a patient in need of same comprising administering a compound is selected from glycyrrhetic acid derivatives, progesterone and progesterone derivatives.

SOME ADVANTAGES

10

One key advantage of the present invention is that the compounds of the present invention can act as 11 β -HSD inhibitors. The compounds may inhibit the interconversion of inactive 11-keto steroids with their active hydroxy equivalents. Thus present invention provides methods by which the conversion of the inactive to the active form may be
15 controlled, and to useful therapeutic effects which may be obtained as a result of such control. More specifically, but not exclusively, the invention is concerned with interconversion between cortisone and cortisol in humans.

- Another advantage of the compounds of the present invention is that they may be potent
20 11 β -HSD inhibitors *in vivo*.

Some of the compounds of the present invention are also advantageous in that they may be orally active.

- 25 The present invention may provide for a medicament for one or more of (i) regulation of carbohydrate metabolism, (ii) regulation of protein metabolism, (iii) regulation of lipid metabolism, (iv) regulation of normal growth and/or development, (v) influence on cognitive function, (vi) resistance to stress and mineralocorticoid activity.

- 30 Some of the compounds of the present invention may also be useful for inhibiting hepatic gluconeogenesis. The present invention may also provide a medicament to relieve the effects of endogenous glucocorticoids in diabetes mellitus, obesity (including centripetal obesity), neuronal loss and/or the cognitive impairment of old age. Thus, in a further aspect, the invention provides the use of an inhibitor of 11 β -HSD in the manufacture of a
35 medicament for producing one or more therapeutic effects in a patient to whom the


medicament is administered, said therapeutic effects selected from inhibition of hepatic gluconeogenesis, an increase in insulin sensitivity in adipose tissue and muscle, and the prevention of or reduction in neuronal loss/cognitive impairment due to glucocorticoid-potentiated neurotoxicity or neural dysfunction or damage.

5

From an alternative point of view, the invention provides a method of treatment of a human or animal patient suffering from a condition selected from the group consisting of: hepatic insulin resistance, adipose tissue insulin resistance, muscle insulin resistance, neuronal loss or dysfunction due to glucocorticoid potentiated neurotoxicity, and any
 10 combination of the aforementioned conditions, the method comprising the step of administering to said patient a medicament comprising a pharmaceutically active amount of a compound in accordance with the present invention (a compound selected from glycyrrhetic acid derivatives, progesterone and progesterone derivatives).

15 PREFERRED ASPECTS

In one preferred aspect the compound for use in the present invention is of formula I or a salt thereof



Formula I


wherein R1 is selected from H, alkyl, cycloalkyl, alkenyl, aryl, =O, OH, O-alkyl, O-acyl
 20 and O-aryl

and R2 is selected from H, =O, OH, hydrocarbyl, oxyhydrocarbyl, and halo;

R5 to R9 are independently selected from H and hydrocarbyl

R3 and R4 together represent

(i) a group of formula II




Formula II

wherein R10 is selected from OH, hydrocarbyl, N-hydrocarbyl and O-hydrocarbyl;

wherein when R1 is OH, R10 is hydrocarbyl, N-hydrocarbyl or O-hydrocarbyl

R11 and R12 are independently selected from H and hydrocarbyl, or

(ii) a group of formula III



Formula III

5 wherein R13 is hydrocarbyl and R14 is H or OH, or R13 and R14 together represent =O.

The compound of or for use in the present invention may be substituted with additional substituents to those specifically recited in the general formulae of the present
10 specification or may contain one or more further bonds/degrees of unsaturation.

The term "hydrocarbyl group" as used herein means a group comprising at least C and H and may optionally comprise one or more other suitable substituents. Examples of such substituents may include halo, alkoxy, nitro, an alkyl group, a cyclic group etc. In
15 addition to the possibility of the substituents being a cyclic group, a combination of substituents may form a cyclic group. If the hydrocarbyl group comprises more than one C then those carbons need not necessarily be linked to each other. For example, at least two of the carbons may be linked via a suitable element or group. Thus, the hydrocarbyl group may contain hetero atoms. Suitable hetero atoms will be apparent to
20 those skilled in the art and include, for instance, sulphur, nitrogen and oxygen. A non-limiting example of a hydrocarbyl group is an acyl group.

A typical hydrocarbyl group is a hydrocarbon group. Here the term "hydrocarbon" means any one of an alkyl group, an alkenyl group, an alkynyl group, which groups may be
25 linear, branched or cyclic, or an aryl group. The term hydrocarbon also includes those

groups but wherein they have been optionally substituted. If the hydrocarbon is a branched structure having substituent(s) thereon, then the substitution may be on either the hydrocarbon backbone or on the branch; alternatively the substitutions may be on the hydrocarbon backbone and on the branch.

5

Typical hydrocarbyl groups are C₁-C₁₀ hydrocarbyl, C₁-C₅ hydrocarbyl or C₁-C₃ hydrocarbyl.

Typical hydrocarbon groups are C₁-C₁₀ hydrocarbon, C₁-C₅ hydrocarbon, C₁-C₃ hydrocarbon, alkyl groups, C₁-C₁₀ alkyl, C₁-C₅ alkyl and C₁-C₃ alkyl.

10

The hydrocarbyl/hydrocarbon/alkyl may be straight chain or branched and/or may be saturated or unsaturated.

15 The term "oxyhydrocarbyl" group as used herein means a group comprising at least C, H and O and may optionally comprise one or more other suitable substituents. Examples of such substituents may include halo-, alkoxy-, nitro-, an alkyl group, a cyclic group etc. In addition to the possibility of the substituents being a cyclic group, a combination of substituents may form a cyclic group. If the oxyhydrocarbyl group comprises more than
20 one C then those carbons need not necessarily be linked to each other. For example, at least two of the carbons may be linked *via* a suitable element or group. Thus, the oxyhydrocarbyl group may contain hetero atoms. Suitable hetero atoms will be apparent to those skilled in the art and include, for instance, sulphur and nitrogen.

25 In one embodiment of the present invention, the oxyhydrocarbyl group is a oxyhydrocarbon group.

Here the term "oxyhydrocarbon" means any one of an alkoxy group, an oxyalkenyl group, an oxyalkynyl group, which groups may be linear, branched or cyclic, or an
30 oxyaryl group. The term oxyhydrocarbon also includes those groups but wherein they have been optionally substituted. If the oxyhydrocarbon is a branched structure having substituent(s) thereon, then the substitution may be on either the hydrocarbon backbone or on the branch; alternatively the substitutions may be on the hydrocarbon backbone and on the branch.

35

Typically, the oxyhydrocarbonyl group is of the formula $C_{1-8}O$ (such as a $C_{1-3}O$).

In one preferred aspect R1 is selected from =O, OH, O-aryl, O-acyl and O-alkyl.

5 In one preferred aspect R1 is O-CH₂-CH₂-Ph.

In one preferred aspect R1 is O-Me, O-Et or O-CH₂-cyclohexyl.


In one preferred aspect R2 is selected from H, =O, OH, O-alkylaryl, and halo.

10

In one preferred aspect R2 is selected from H, =O, OH, O-CH₂-Ph and F.

In one preferred aspect R2 is =O or OH.


15 In one preferred aspect R3 and R4 together represent a group of formula IV



Formula IV

wherein R10, R11 and R12 are as defined above.

In one preferred aspect R3 and R4 together represent a group of formula V




Formula V

wherein R10, R11 and R12 are as defined above.

20

In the combination of these two preferred aspects R3 and R4 together represent a group of formula VI

Formula VI



R10 of the compounds of the present invention is selected from OH, hydrocarbyl, N-hydrocarbyl and O-hydrocarbyl. It will be appreciated that hydrocarbyl includes hydrocarbyl groups containing hetero atoms linking two carbons or linking one carbon to the compound of the invention. Thus hydrocarbyl incorporates for example N-hydrocarbyl and O-hydrocarbyl.

In one aspect R10 is a group of the formula $-NR_{18}R_{19}$ wherein R_{18} and R_{19} are independently selected from hydrogen and hydrocarbyl or together represent a cyclic hydrocarbyl group. In a preferred aspect one of R_{18} and R_{19} is other than hydrogen. In particularly preferred embodiments R_{18} and R_{19} are independently selected from H, $(CH_2)_{0.5}Ph$, $CH(C_{1-8} \text{ alkyl})COOC_2H_5$, $CH(C_{1-8} \text{ alkyl})COOH$, cyclopropane, optionally substituted pyridine, optionally substituted morpholine, $(CH_2)_{0.5}OH$ or R_{18} and R_{19} together represent a heterocyclic group. In particularly preferred embodiments R_{18} and R_{19} are independently selected from H, CH_2Ph , $CH(CH_3)COOC_2H_5$, $CH(CH_3)COOH$, cyclopropane, 2-methylpyridine, 2-(4-ethylmorpholine), $CH_2(CH_2)_4OH$ or R_{18} and R_{19} together represent piperidine.

In one preferred aspect R10 is selected from OH and OMe.

In one preferred aspect R11 is Me.

In one preferred aspect R12 is Me.

In one preferred aspect R13 together with R14 is $=O$ or R13 is a group of the formula $C(R_{15})(R_{16})(R_{17})$ wherein R15 is alkyl or a hydroxy-substitute alkyl; and either (a) R16 is $-OH$ or hydrocarbyl and R17 is H; or (b) R16 together with R17 is $=O$

In one preferred aspect R14 is H.

In one preferred aspect R5 is Me.

In one preferred aspect R6 is Me or H.

5


In one preferred aspect R7 is Me.

In one preferred aspect R8 is H, Me or a bond with the carbon common with the adjacent ring.


10

In one preferred aspect R9 is H or Me.


Particularly preferred compounds of the present invention are the those given below



BLE99005




Progesterone

Progesterone-3 β ,11 β ,20 β -triol

DG326


13

DG320




The present invention provides a use to inhibit Type 1 and/or Type 2 11 β -HSD. In one aspect the present invention provides a use as defined herein to inhibit 11 β -HSD Type 1 activity. In this aspect preferred compounds are


BLE99005



Progesterone



11-keto-Progesterone




5

In one aspect the present invention provides a use as defined herein to inhibit 11 β -HSD Type 2 activity. In this aspect preferred compounds are


Progesterone-3 β ,11 β ,20 β -triol

DG326




14

DG320




STX 350




A number of compounds of the present invention are novel. In one aspect the present invention provides a use wherein the compound is a novel compound of formula I or a salt thereof

Formula I




- 5 wherein R1 is OH, O-alkyl, O-acyl or O-aryl
and R2 is selected from H, =O, OH, hydrocarbyl, oxyhydrocarbyl, and halo;
R5 to R9 are independently selected from H and hydrocarbyl
R3 and R4 together represent a group of formula II

Formula II



- wherein R10 is selected from OH, hydrocarbyl, N-hydrocarbyl and O-hydrocarbyl, R11
10 and R12 are independently selected from H and hydrocarbyl,
wherein when R1 is OH, R10 is N-hydrocarbyl.

In one aspect the present invention provides a use wherein the compound is a novel compound of formula I or a salt thereof




Formula I

wherein R1 is selected from H, alkyl, cycloalkyl, alkenyl, aryl, =O, OH, O-alkyl, O-acyl
5 and O-aryl; and

R2 is oxyhydrocarbyl

R5 to R9 are independently selected from H and hydrocarbyl

R3 and R4 together represent a group of formula III




Formula II

wherein R13 is hydrocarbyl and R14 is H or OH, or R13 and R14 together represent =O.

10

In a further aspect the present invention provides a compound of formula I or a salt thereof




Formula I

wherein R1 is OH, O-alkyl, O-acyl or O-aryl

and R2 is selected from H, =O, OH, hydrocarbyl, oxyhydrocarbyl, and halo;

15 R5 to R9 are independently selected from H and hydrocarbyl


R3 and R4 together represent a group of formula II



Formula II

wherein R10 is selected from OH, hydrocarbyl, N-hydrocarbyl and O-hydrocarbyl, R11 and R12 are independently selected from H and hydrocarbyl, wherein when R1 is OH, R10 is N-hydrocarbyl.

- 5 In a further aspect the present invention provides a compound of formula I or a salt thereof




Formula I

wherein R1 is O-alkyl, O-acyl or O-aryl

and R2 is selected from H, =O, OH, hydrocarbyl, oxyhydrocarbyl, and halo;

R5 to R9 are independently selected from H and hydrocarbyl


- 10 R3 and R4 together represent a group of formula II



Formula II

wherein R10 is selected from OH, hydrocarbyl, N-hydrocarbyl and O-hydrocarbyl, R11 and R12 are independently selected from H and hydrocarbyl.

- 15 In a further aspect the present invention provides a compound of formula I or a salt thereof




Formula I

wherein R₁ is selected from H, alkyl, cycloalkyl, alkenyl, aryl, =O, OH, O-alkyl, O-acyl and O-aryl; and

R₂ is oxyhydrocarbonyl

R₅ to R₉ are independently selected from H and hydrocarbonyl

5 R₃ and R₄ together represent a group of formula III



Formula II

wherein R₁₃ is hydrocarbonyl and R₁₄ is H or OH, or R₁₃ and R₁₄ together represent =O.

In these aspects wherein a novel compound is provided, preferably R₁ is O-CH₂-CH₂-Ph; and/or R₁ is O-Me, O-Et or O-CH₂-cyclohexyl; and/or R₂ is O-CH₂-Ph.

10

In a further aspect the present invention provides a pharmaceutical composition comprising a novel compound as described herein optionally admixed with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

15 In a further aspect the present invention provides a novel compound as described herein for use in medicine.

THERAPY

20 The compounds of the present invention may be used as therapeutic agents – i.e. in therapy applications.

The term "therapy" includes curative effects, alleviation effects, and prophylactic effects.

25 The therapy may be on humans or animals.

PHARMACEUTICAL COMPOSITIONS

In one aspect, the present invention provides a pharmaceutical composition, which comprises a compound according to the present invention and optionally a
5 pharmaceutically acceptable carrier, diluent or excipient (including combinations thereof).

The pharmaceutical compositions may be for human or animal usage in human and veterinary medicine and will typically comprise any one or more of a pharmaceutically acceptable diluent, carrier, or excipient. Acceptable carriers or diluents for therapeutic
10 use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A.R.Gennaro edit. 1985). The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as - or in addition to - the carrier, excipient
15 or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s).

Preservatives, stabilisers, dyes and even flavouring agents may be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate,
20 sorbic acid and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may be also used.

There may be different composition/formulation requirements dependent on the different delivery systems. By way of example, the pharmaceutical composition of the present
25 invention may be formulated to be delivered using a mini-pump or by a mucosal route, for example, as a nasal spray or aerosol for inhalation or ingestible solution, or parenterally in which the composition is formulated by an injectable form, for delivery, by, for example, an intravenous, intramuscular or subcutaneous route. Alternatively, the formulation may be designed to be delivered by both routes.

30

Where the agent is to be delivered mucosally through the gastrointestinal mucosa, it should be able to remain stable during transit through the gastrointestinal tract; for example, it should be resistant to proteolytic degradation, stable at acid pH and resistant to the detergent effects of bile.

35

Where appropriate, the pharmaceutical compositions can be administered by inhalation, in the form of a suppository or pessary, topically in the form of a lotion, solution, cream, ointment or dusting powder, by use of a skin patch, orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture
5 with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents, or they can be injected parenterally, for example intravenously, intramuscularly or subcutaneously. For parenteral administration, the compositions may be best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic
10 with blood. For buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.

COMBINATION PHARMACEUTICAL

15

The compound of the present invention may be used in combination with one or more other active agents, such as one or more other pharmaceutically active agents.

By way of example, the compounds of the present invention may be used in combination
20 with other 11 β -HSD inhibitors.

ADMINISTRATION

Typically, a physician will determine the actual dosage which will be most suitable for an
25 individual subject and it will vary with the age, weight and response of the particular patient. The dosages below are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited.

The compositions of the present invention may be administered by direct injection. The
30 composition may be formulated for parenteral, mucosal, intramuscular, intravenous, subcutaneous, intraocular or transdermal administration. Depending upon the need, the agent may be administered at a dose of from 0.01 to 30 mg/kg body weight, such as from 0.1 to 10 mg/kg, more preferably from 0.1 to 1 mg/kg body weight.

By way of further example, the agents of the present invention may be administered in accordance with a regimen of 1 to 4 times per day, preferably once or twice per day. The specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound
5 employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.

Aside from the typical modes of delivery – indicated above – the term “administered” also
10 includes delivery by techniques such as lipid mediated transfection, liposomes, immunoliposomes, lipofectin, cationic facial amphiphiles (CFAs) and combinations thereof. The routes for such delivery mechanisms include but are not limited to mucosal, nasal, oral, parenteral, gastrointestinal, topical, or sublingual routes.

15 The term “administered” includes but is not limited to delivery by a mucosal route, for example, as a nasal spray or aerosol for inhalation or as an ingestible solution; a parenteral route where delivery is by an injectable form, such as, for example, an intravenous, intramuscular or subcutaneous route.

20 Thus, for pharmaceutical administration, the 11 β -HSD inhibitors of the present invention can be formulated in any suitable manner utilising conventional pharmaceutical formulating techniques and pharmaceutical carriers, adjuvants, excipients, diluents etc. and usually for parenteral administration. Approximate effective dose rates may be in the range from 1 to 1000 mg/day, such as from 10 to 900 mg/day or even from 100 to
25 800 mg/day depending on the individual activities of the compounds in question and for a patient of average (70Kg) bodyweight. More usual dosage rates for the preferred and more active compounds will be in the range 200 to 800 mg/day, more preferably, 200 to 500 mg/day, most preferably from 200 to 250 mg/day. They may be given in single dose regimes, split dose regimes and/or in multiple dose regimes lasting over several days.
30 For oral administration they may be formulated in tablets, capsules, solution or suspension containing from 100 to 500 mg of compound per unit dose. Alternatively and preferably the compounds will be formulated for parenteral administration in a suitable parenterally administrable carrier and providing single daily dosage rates in the range 200 to 800 mg, preferably 200 to 500, more preferably 200 to 250 mg. Such effective
35 daily doses will, however, vary depending on inherent activity of the active ingredient and

on the bodyweight of the patient, such variations being within the skill and judgement of the physician.

The compounds of the present invention may be useful in the manufacture of a
5 medicament for revealing an endogenous glucocorticoid-like effect.

OTHER THERAPIES

It is also to be understood that the compound/composition of the present invention may
10 have other important medical implications.

For example, the compound or composition of the present invention may be useful in the treatment of the disorders listed in WO-A-99/52890 – viz:

15 In addition, or in the alternative, the compound or composition of the present invention may be useful in the treatment of the disorders listed in WO-A-98/05635. For ease of reference, part of that list is now provided: cancer, inflammation or inflammatory disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response, cachexia, anorexia, acute infection, HIV infection, shock states,
20 graft-versus-host reactions, autoimmune disease, reperfusion injury, meningitis, migraine and aspirin-dependent anti-thrombosis; tumour growth, invasion and spread, angiogenesis, metastases, malignant, ascites and malignant pleural effusion; cerebral ischaemia, ischaemic heart disease, osteoarthritis, rheumatoid arthritis, osteoporosis, asthma, multiple sclerosis, neurodegeneration, Alzheimer's disease, atherosclerosis,
25 stroke, vasculitis, Crohn's disease and ulcerative colitis; periodontitis, gingivitis; psoriasis, atopic dermatitis, chronic ulcers, epidermolysis bullosa; corneal ulceration, retinopathy and surgical wound healing; rhinitis, allergic conjunctivitis, eczema, anaphylaxis; restenosis, congestive heart failure, endometriosis, atherosclerosis or endosclerosis.

30 In addition, or in the alternative, the compound or composition of the present invention may be useful in the treatment of disorders listed in WO-A-98/07859. For ease of reference, part of that list is now provided: cytokine and cell proliferation/differentiation activity; immunosuppressant or immunostimulant activity (e.g. for treating immune
35 deficiency, including infection with human immune deficiency virus; regulation of

lymphocyte growth; treating cancer and many autoimmune diseases, and to prevent transplant rejection or induce tumour immunity); regulation of haematopoiesis, e.g. treatment of myeloid or lymphoid diseases; promoting growth of bone, cartilage, tendon, ligament and nerve tissue, e.g. for healing wounds, treatment of burns, ulcers and periodontal disease and neurodegeneration; inhibition or activation of follicle-stimulating hormone (modulation of fertility); chemotactic/chemokinetic activity (e.g. for mobilising specific cell types to sites of injury or infection); haemostatic and thrombolytic activity (e.g. for treating haemophilia and stroke); antiinflammatory activity (for treating e.g. septic shock or Crohn's disease); as antimicrobials; modulators of e.g. metabolism or behaviour; as analgesics; treating specific deficiency disorders; in treatment of e.g. psoriasis, in human or veterinary medicine.

In addition, or in the alternative, the composition of the present invention may be useful in the treatment of disorders listed in WO-A-98/09985. For ease of reference, part of that list is now provided: macrophage inhibitory and/or T cell inhibitory activity and thus, anti-inflammatory activity; anti-immune activity, i.e. inhibitory effects against a cellular and/or humoral immune response, including a response not associated with inflammation; inhibit the ability of macrophages and T cells to adhere to extracellular matrix components and fibronectin, as well as up-regulated fas receptor expression in T cells; inhibit unwanted immune reaction and inflammation including arthritis, including rheumatoid arthritis, inflammation associated with hypersensitivity, allergic reactions, asthma, systemic lupus erythematosus, collagen diseases and other autoimmune diseases, inflammation associated with atherosclerosis, arteriosclerosis, atherosclerotic heart disease, reperfusion injury, cardiac arrest, myocardial infarction, vascular inflammatory disorders, respiratory distress syndrome or other cardiopulmonary diseases, inflammation associated with peptic ulcer, ulcerative colitis and other diseases of the gastrointestinal tract, hepatic fibrosis, liver cirrhosis or other hepatic diseases, thyroiditis or other glandular diseases, glomerulonephritis or other renal and urologic diseases, otitis or other oto-rhino-laryngological diseases, dermatitis or other dermal diseases, periodontal diseases or other dental diseases, orchitis or epididymo-orchitis, infertility, orchidial trauma or other immune-related testicular diseases, placental dysfunction, placental insufficiency, habitual abortion, eclampsia, pre-eclampsia and other immune and/or inflammatory-related gynaecological diseases, posterior uveitis, intermediate uveitis, anterior uveitis, conjunctivitis, chorioretinitis, uveoretinitis, optic neuritis, intraocular inflammation, e.g. retinitis or cystoid macular oedema, sympathetic

ophthalmia, scleritis, retinitis pigmentosa, immune and inflammatory components of degenerative fondus disease, inflammatory components of ocular trauma, ocular inflammation caused by infection, proliferative vitreo-retinopathies, acute ischaemic optic neuropathy, excessive scarring, e.g. following glaucoma filtration operation, immune
5 and/or inflammation reaction against ocular implants and other immune and inflammatory-related ophthalmic diseases, inflammation associated with autoimmune diseases or conditions or disorders where, both in the central nervous system (CNS) or in any other organ, immune and/or inflammation suppression would be beneficial, Parkinson's disease, complication and/or side effects from treatment of Parkinson's
10 disease, AIDS-related dementia complex HIV-related encephalopathy, Devic's disease, Sydenham chorea, Alzheimer's disease and other degenerative diseases, conditions or disorders of the CNS, inflammatory components of stokes, post-polio syndrome, immune and inflammatory components of psychiatric disorders, myelitis, encephalitis, subacute sclerosing pan-encephalitis, encephalomyelitis, acute neuropathy, subacute neuropathy,
15 chronic neuropathy, Guillain-Barre syndrome, Sydenham chora, myasthenia gravis, pseudo-tumour cerebri, Down's Syndrome, Huntington's disease, amyotrophic lateral sclerosis, inflammatory components of CNS compression or CNS trauma or infections of the CNS, inflammatory components of muscular atrophies and dystrophies, and immune and inflammatory related diseases, conditions or disorders of the central and peripheral
20 nervous systems, post-traumatic inflammation, septic shock, infectious diseases, inflammatory complications or side effects of surgery, bone marrow transplantation or other transplantation complications and/or side effects, inflammatory and/or immune complications and side effects of gene therapy, e.g. due to infection with a viral carrier, or inflammation associated with AIDS, to suppress or inhibit a humoral and/or cellular
25 immune response, to treat or ameliorate monocyte or leukocyte proliferative diseases, e.g. leukaemia, by reducing the amount of monocytes or lymphocytes, for the prevention and/or treatment of graft rejection in cases of transplantation of natural or artificial cells, tissue and organs such as cornea, bone marrow, organs, lenses, pacemakers, natural or artificial skin tissue.

30

The present invention will now be described in further detail by way of example only with reference to the accompanying figures in which:-

Figure 1 shows a graph;

35 Figure 2 shows a graph;

Figure 3 shows a graph;
Figure 4 shows a graph;
Figure 5 shows a graph;
Figure 6 shows a graph;
5 Figure 7 shows a graph;
Figure 8 shows a graph;
Figure 9 shows a graph;
Figure 10 shows a graph; and
Figure 11 shows a graph.

10

The present invention will now be described in further detail in the following examples.

EXAMPLES

15 **MATERIALS AND METHODS**

Materials

Enzymes - Rat livers and rat kidneys were obtained from normal Wistar rats (Harlan
20 Olac, Bicester, Oxon, UK). Both the kidneys and livers were homogenised on ice in PBS-
sucrose buffer (1g/ 10 ml) using an Ultra-Turrax. After the livers and kidneys were
homogenised the homogenate was centrifuged for five minutes at 4000 rpm. The
supernatant obtained was removed and stored in glass vials at -20°C. The amount of
protein per µl of rat liver and kidney cytosol was determined using the Bradford method
25 [14].

Apparatus

- Incubator: mechanically shaken water bath, SW 20, Germany.
- Evaporator, Techne Driblock DB 3A, UK
- 30 • TLC aluminium sheets 20 x 20 cm silica gel 60 F₂₅₄, Merck, Germany.
- Scintillation vials: 20 ml polypropylene vials with caps, SARSTEDT, Germany.
- Scintillation counter: Beckman LS 6000 SC, Beckman Instruments Inc., USA.

Solutions

- 35 • Assay medium: PBS-sucrose buffer, Dulbecco's Phosphate Buffered Saline, 1

tablet/100 ml with 0,25 M sucrose, pH 7,4 BDH Laboratory supplies, UK.

- Scintillation fluid: Ecoscint A (National Diagnostics, USA).
- Radioactive compound solutions: [1,2,6,7-³H]-cortisol (Sp. Ac. 84 Ci/mmol) NEN Germany, [4-¹⁴C]-cortisol (Sp. Ac. 53 mCi/mmol) NEN Germany.
- 5 • CrO₃ and Acetic acid (Sigma Chemical Co., UK).
- Extraction fluid: Di-ethylether, Fischer Chemicals, UK.
- Bradford Reagent solution: Coomassie Brilliant Blue G-250, 100 mg in 95% ethanol with 100 ml of phosphoric acid (85% w/v) diluted to 1 litre.

10 Compounds


- Inhibitors: compounds were obtained from Sigma Chemical Co., UK or were synthesised in accordance with the synthetic routes below or as described in Appendix I.
- Cofactor: NADPH and NADP, Sigma Chemical Co., UK.

15

SYNTHETIC ROUTES

11 α -HYDROXY PROGESTERONE DERIVATIVES


20 11 α -benzyloxyprogesterone (DG 316 A) (1)



- To a stirred solution of 11 α -Hydroxy progesterone (3 g; 9.1 mmol; 1 equiv.) in dry DMF (75 ml) at 0 °C, NaH (1.09 g; 27.2 mmol; 3 equiv.) was added followed by benzyl bromide (3.84 ml; 32.25 mmol; 3.5 equiv.). After the evolution of H₂ had ceased, the reaction mixture was refluxed for 25 mins, cooled and poured in to ice-H₂O containing 3M HCl. The resulting mixture was extracted with ethyl acetate (3×100 ml), washed with H₂O (3×100 ml) followed by brine (3×100 ml), dried with MgSO₄, filtered and evaporated under reduced pressure to give a yellow solid (2.99 g; 18 mmol), which was purified by recrystallisation with hot absolute ethanol to give **1** as a pale yellow crystals (1.17 g; 30%). R_f: 0.89 (CHCl₃ : methanol = 9 : 1); m.p. : 207 – 210 °C; MS (FAB⁺) m/z (rel.
- 30

intensity) : 421.3 [30, (M+H)⁺], 91.0 [100, (PhCH₂+H)⁺]; MS (FAB⁺) m/z (rel. intensity) : 419.3 [100, (M-H)⁻]; Acc. MS m/z (FAB⁺) : 421.2640, C₂₈H₃₇O₃ requires 421.2619.

11 α -benzyloxy-3,20-dihydroxyprogesterone (DG 354 B) (2)




5 1 (700 mg; 1.66 mmol; 1 equiv.) in freshly distilled THF (50 ml) was cooled to 0 °C and was added LiAlH₄ (221 mg; 5.8 mmol; 3.5 equiv.) in small portions and stirred until all of the H₂ had evolved. This mixture was refluxed for 2 hrs under N₂, cooled to R.T., aqueous MgSO₄ followed by solid MgSO₄ was added. The solution was filtered off and
10 the filtrate was evaporated under reduced pressure to give a white solid (722 mg), which was purified by flash chromatography (CHCl₃/ethyl acetate gradient, 8:1 to 2:1) and the white solid isolated (376 mg) was recrystallised from ethyl acetate/hexane to give 2 (187 mg; 18%) as white crystals. R_f: 0.86 (CHCl₃ : methanol = 9 : 1); m.p. : 117 - 118 °C. MS (FAB⁺) m/z (rel. intensity) : 425.1 [100, (M+H)⁺], 91.0 [70, (PhCH₂+H)⁺]; MS (FAB⁻) m/z
15 (rel. intensity) : 423.1 [100, (M-H)⁻].

Synthesis of Jones' Reagent (3)

To a solution of Chromium trioxide (2.8 g) in water (200 ml) was stirred and cooled to
20 °C. To this solution conc. H₂SO₄ (0.7 ml) was added cautiously and stirred. This solution was used for the oxidation reactions of the 11 α -Hydroxy progesterone and 18 β -Glycerrhetenic acid.


11-Oxo-progesterone (DG 322 A) (STX 124) (4)



25 Jones reagent (1 ml) was added to a solution of 11 α -Hydroxy progesterone (100 mg; 0.3 mmol; 1 equiv.) in acetone (15 ml). After stirring for 30 mins at 0 °C, the reaction mixture was poured into ice-H₂O and extracted with CHCl₃ (3×50 ml), washed with H₂O (3×50


ml), dried with MgSO_4 , filtered and evaporated under reduced pressure to give a white solid (80 mg), which was purified by recrystallisation with hot absolute ethanol to give 4 as white needles (66 mg; 66%). R_f : 0.86 (CHCl_3 : methanol = 9 : 1); m.p. : 182 – 183 °C (Lit. m.p. : 178 - 179 °C); MS (FAB⁺) m/z (rel. intensity) : 329.1 [100, (M+H)⁺]; MS (FAB⁻) m/z (rel. intensity) : 327.1 [100, (M-H)⁻].

3,11,20- Trihydroxyprogesterone (DG 326 B) (STX 125) (5)



A solution of 11 α -Hydroxy progesterone (1 g; 3 mmol) in freshly distilled THF (100 ml) was cooled to 0 °C and was added LiAlH_4 (345 mg; 9.1) in small portions and stirred until all of the H_2 had evolved. This mixture was refluxed for 2 hrs under N_2 , cooled to R.T., aqueous MgSO_4 followed by solid MgSO_4 was added. The solution was filtered off and the filtrate was evaporated under reduced pressure to give a white solid (3.91 g), which was purified by recrystallisation from ethyl acetate/hexane to give 5 (740 mg; 73%) as white crystals. R_f : 0.39 (CHCl_3 : methanol = 9 : 1); m.p. : 122 - 125 °C; MS (FAB⁺) m/z (rel. intensity) : 281.2 [30, (M-3OH+H)⁺], 299.2 [55, (M-2OH+H)⁺], 317.2 [100, (M-OH+H)⁺], 333.2 [70, (M+H)⁺]; MS (FAB⁻) m/z (rel. intensity) : 331.2 [100, (M+H)⁻]; Acc. MS m/z (FAB⁺): 335.2532, $\text{C}_{21}\text{H}_{35}\text{O}_3$ requires 335.2586.


11 α -Fluoroprogesterone (DG 375 B) (STX 123) (6)



A solution of 11 α -Hydroxy progesterone (1 g; 3 mmol; 1 equiv.) in anhydrous DCM (50 ml) was cooled to 0 °C under N_2 and was added DAST (0.5 ml; 3.6 mmol; 1.2 equiv.) dropwise, slowly and stirred until the mixture was warmed to R.T. After stirring for 10 mins, ice- H_2O was added cautiously and extracted with CHCl_2 (3×50 ml), washed with H_2O (3×50 ml), dried with MgSO_4 , filtered and evaporated under reduced pressure to give a yellow solid (642 mg), which was purified by flash chromatography

(CHCl₃/methanol gradient, 10:1 to 6:1) and the yellow solid isolated (522 mg) was recrystallised with hot absolute ethanol to give **6** as yellow crystals (322 mg; 33%). *R_f*: 0.86 (CHCl₃ : methanol = 9 : 1); *m.p.* : 119 - 120 °C; **MS** (FAB⁺) *m/z* (rel. intensity) : 313.3 [20, (M+H)⁺]; 313.3 [100, (M-F+H)⁺]; **Acc. MS** *m/z* (FAB⁺) : 333.2227, C₂₁H₃₀FO₂ requires 333.2229.

11 α -Methoxyprogesterone (DG 357 B) (STX 193) (7)




A solution of 11 α -Hydroxy progesterone (1 g; 3 mmol) in anhydrous DMF (100 ml) containing anhydrous K₂CO₃ (1 g; 3 mmol) was stirred at R.T. under N₂ for 1 hour. Methyl iodide (1 g; 3 mmol) was introduced to the reaction mixture followed by tetra butyl ammonium iodide (1 g; 3 mmol). The resulting mixture was stirred for 24 hours at R.T. The resulting mixture was poured in to brine and the organics were extracted with ethyl acetate (3×200 ml), washed with H₂O (3×100 ml), dried with MgSO₄, filtered and evaporated under reduced pressure to give a pale yellow solid (954 mg), which was purified flash chromatography (CHCl₃/methanol gradient, 10:1 to 6:1) and the yellow solid isolated (896 mg) was recrystallised with hot absolute ethanol to give **7** as white crystals (800 mg; 81%). *R_f*: 0.71 (CHCl₃ : methanol = 9 : 1); *m.p.* : 164 - 165 °C; **MS** (FAB⁺) *m/z* (rel. intensity) : 345.1 [100, (M+H)⁺]; **HPLC** : [Sperisorb ODS5 column (25 × 4.6 mm) : Mobile phase, MeOH:H₂O (70:30); Flow rate = 2 ml/min, λ_{max} = 254 nm; *t_R* = 9.09 min.

18 β -GLYCERRHETINIC ACID DERIVATIVES

3,11-Dioxo-18 α -olean-12-en-30-oic acid STX51 (BLE99005)

Jones reagent (0.1 ml, 2.67 M) was added to a solution of 18 α -glycyrhretinic acid (100 mg, 0.21 mmol) in 10 ml THF at 0°C for 30 min. The reaction mixture was poured into a mixture of ice-water (50 ml). The resulting precipitate was filtered off and then dissolved in chloroform (100 ml). The solution was washed with water, dried over MgSO₄ and evaporated *in vacuo*. The residue obtained was recrystallised from EtOH (15 ml) to give

66 mg (66%) of 3,11-dioxo-18 α -olean-12-en-30-oic acid **STX51 (BLE99005)** as a white solid after drying at the vacuum pump 3 h at 60°C under P₂O₅.



STX51 (BLE99005)

5

Ref. : T.Terasawa, T. Okada, T. Hara, K. Itoh, *Eur. J. Med. Chem.*, 1992, **27**, 354-351.

C₃₀H₄₄O₄

10 MW 468.68

Mp 329 – 333 °C (litt. > 310°C)

¹H NMR 400 MHz (CDCl₃) : 0.74 (s, 3H, C-28-CH₃), 1.07 (s, 3H, C-24-CH₃), 1.10 (s, 3H, C-23-CH₃), 1.20 (s, 3H, C-26-CH₃), 1.26 (s, 3H, C-29-CH₃), 1.33 (s, 3H, C-29-CH₃), 1.35 (s, 3H, C-27-CH₃), 1.15-1.76 (m, 17H), 1.98 (m, 2H), 2.25 (m, 1H), 2.34 (m, 1H), 2.64 (m, 1H), 2.86 (m, 1H), 5.64 (s br, 1H, 12-H).

15

M/S *m/z* (+ve FAB, rel. int.) : 469.3 [100, (M+H)⁺], 420.3 (12), 330.1 (12), 303.2 (17), 272.1 (11), 256.2 (14), 243.2 (14), 173.1 (17), 157.1 (11), 131.1 (14), 111.1 (12), 75 (11).

20

M/S *m/z* (-ve FAB, rel. int.) : 467.4 [100, (M-H)⁻], 456.2 (24), 276.1 (36).

HRMS (+ve FAB) *m/z* calcd for C₃₀H₄₅O₄ (MH⁺) 469.33178, found 469.33208


25 R_f 0.50 (MeOH:CHCl₃ = 90:10), SM R_f 0.36 (MeOH:CHCl₃ = 90:10)

3-Oxo-oleanoic acid STX50 (BLE99006)

Jones reagent (0.05 ml, 2.67 M) was added to a solution of oleanolic acid (50 mg, 0.11 mmol) in 5 ml acetone at 0°C for 45 min. The reaction mixture was poured into a mixture

30

of ice-water (25 ml). The resulting precipitate was filtered off and then dissolved in chloroform (50 ml). The solution was washed with water, dried over MgSO_4 and evaporated *in vacuo*. The crude product was purified by flash chromatography (column $\varnothing = 1.5$ cm, $h = 14$ cm) using as eluent $\text{MeOH}:\text{CHCl}_3 = 99:1$ to obtain 27 mg (54% yield) of 3-oxo-oleanoic acid **STX50 (BLE99006)** as white solid after drying at the vacuum pump 4 h at 60°C under P_2O_5 .



STX50 (BLE99006)

Ref. : Kagei et al., *Yakugaku Zasshi*, **99**, 1979, 583-585.

$\text{C}_{30}\text{H}_{46}\text{O}_3$

MW 454.70

Mp $150\text{--}153^\circ\text{C}$ (hexane) – litt. $161\text{--}5^\circ\text{C}$ (MeOH)

^1H NMR


400 MHz (CDCl_3) : 0.80 (s, 3H, CH_3), 0.90 (s, 3H, CH_3), 0.93 (s, 3H, CH_3), 1.02 (s, 3H, CH_3), 1.04 (s, 3H, CH_3), 1.08 (s, 3H, CH_3), 1.14 (s, 3H, CH_3), 1.15-2.04 (m, 21H), 2.45 (m, 1H), 2.53 (m, 1H), 2.82 (dd, 1H), 5.29 (s br, 1H, ethylenic H).

M/S m/z (+ve FAB, rel. int.) : 455.2 [78, $(\text{M}+\text{H})^+$], 409.2 (33), 248.1 (100), 203.1 (50).


M/S m/z (-ve FAB, rel. int.) : 453.3 [100, $(\text{M}-\text{H})^-$], 276.1 (15).

HRMS (+ve FAB) m/z calcd for $\text{C}_{30}\text{H}_{47}\text{O}_3$ (MH^+) 455.35252, found 455.35181

Rf 0.61 ($\text{MeOH}:\text{CHCl}_3 = 95:5$)

3-Oxo-18 β -glycerrhetinic acid STX 347 (DG 320 A) (11)

Jones' reagent (1 ml) was added to a solution of 18 β -glycerrhetinic acid (100 mg; 0.21 mmol) in acetone (5 ml). The reaction mixture was stirred for 30 mins at 0 °C. The
 5 resulting orange mixture was poured into ice-water and the organic product was extracted from CHCl₃ (50 ml), washed with water (3×50 ml), dried (MgSO₄) and evaporated to get a white solid (108 mg). The crude product was purified by recrystallisation from hot absolute ethanol to give 11 as white crystals (82 mg; 82%). *R*_f: 0.51 (CHCl₃ : Methanol = 9 : 1); m.p. : 303 – 303 °C (Lit. m.p. : >300 °C); MS (FAB⁺) :
 10 m/z : 469.3 [100, (M+H)⁺]; MS (FAB⁻) m/z : 467.4 [100, (M-H)⁻]; Acc. MS (FAB⁻) : 469.3322, C₃₀H₄₅O₄ requires 469.3318.


11-Deoxo-18 β -glycerrhetinic acid (DG 381 B) (STX 122) (12)

15 A solution of 18 β -glycerrhetinic acid (1 g; 2.12 mmol; 1 equiv.) dissolved in acetic acid (100 ml) was added to PtO₂ (602 mg; 2.65 mmol; 1.25 equiv.) dissolved in acetic acid (5 ml) under an atmosphere of H₂. The mixture was stirred over night at R.T. When the product separated out, the balloon containing the H₂ gas was removed and another portion of acetic acid (15 ml) was added. The mixture was heated on a boiling water bath
 20 and the PtO₂ was filtered out and washed with ethyl acetate. On evaporation of the solvent, a white solid (1.04 g) was obtained, which was purified flash chromatography (CHCl₃/methanol gradient, 10:1 to 6:1) and the white solid isolated (972 mg) was recrystallised with hot absolute ethanol to give 12 as white needles (724 mg; 75%). *R*_f: 0.52 (CHCl₃ : Methanol = 9 : 1); m.p. : 309 - 314 °C (dec.) (Lit. m.p. : >300 °C); MS
 25 (FAB⁺) m/z : 457.0 [100, (M+H)⁺]; MS (FAB⁻) m/z : 455.1 [100, (M-H)⁻]. HPLC : [Sperisorb

ODS5 column (25 × 4.6 mm) : Mobile phase, MeOH:H₂O (85:15); Flow rate = 1 ml/min,
 λ_{\max} = 254 nm; t_R = 6.67 min.


11-Deoxo-3 β -aectoxy-18 β -glycyrrhetic acid benzyl ester

5 **STX 354 (DGS01048 C) (13)**




A solution of **12** (300 mg; 0.66 mmol; 1 equiv.) in anhydrous DMF (20 ml) under N₂ was added NaH (79 mg; 1.98 mmol; 3 equiv.) at 0 °C and stirred until all of the H₂ had
 10 ceased. Benzyl bromide (0.3 ml; 2.31 mmol; 3.5 equiv.) was added to the reaction mixture and stirred for 30 mins at R.T. The resulting mixture was poured in to brine and the resulting precipitate was filtered out, washed with H₂O and dried under vacuum to give a white solid (473 mg), which was purified by flash chromatography (CHCl₃/methanol gradient, 10:1 to 6:1) and the two white solids isolated (169 mg and
 15 151 mg) were recrystallised with hot absolute ethanol **13** (153 mg; 43%) and ethyl acetate/hexane to give **14** as white crystals (139 mg; 39%) respectively. R_f : 0.87 (CHCl₃ : methanol = 9 : 1); m.p. : 207 - 208 °C; MS (FAB⁺) m/z : 588.5 [100, (M+H)⁺], 91.0 [75, (PhCH₂+H)⁺]; MS (FAB⁻) m/z (rel. intensity) : 545.1 [100, (M-H)⁻].



20 **11-Deoxo-3 β -benzyl-18 β -glycyrrhetic acid**





R_f : 0.87 (CHCl₃ : methanol = 9 : 1); m.p. : 207 - 208 °C; MS (FAB⁺) m/z : 547.3 [100, (M+H)⁺], 91.0 [75, (PhCH₂+H)⁺]; MS (FAB⁻) m/z (rel. intensity) : 545.1 [100, (M-H)⁻].
 25

11-Deoxo-3 α -hydroxy-18 β -glycyrrhetic acid benzyl ester(DGS01048 D) (14)

R_f : 0.39 (CHCl_3 : methanol = 9 : 1); m.p. : 151 - 152 °C; MS (FAB⁺) m/z : 547.3 [40, (M+H)⁺], 91.0 [100, (PhCH₂+H)⁺]; Acc. MS (FAB⁺) : 547.4078, C₃₇H₅₅O₃ requires
5 547.4151.


11-Deoxo-3 α -benzyl-18 β -glycyrrhetic acid**11-Oxo-3 β -benzyloxy-18 β -glycyrrhetic acid benzyl ester (DGS01046 C) (15)**

Using the procedure described for the preparation of **13**, a solution of 18 β -glycyrrhetic acid (1 g; 2.12 mmol) in DMF (70 ml), NaH (255 mg; 6.37 mmol) and benzyl bromide (1 ml; 7.44 mmol) gave a white solid (2.1 g), which was purified by flash chromatography
15 (CHCl_3 /methanol gradient, 10:1 to 6:1) and the two white solids isolated (796 mg and 364 mg) were recrystallised with hot acetone to give **15** (153 mg; 43%) and **16** (139 mg; 39%) as white crystals respectively. R_f : 0.93 (CHCl_3 : methanol = 9 : 1); m.p. : 207 - 209 °C; MS (FAB⁺) m/z : 651.3 [100, (M+H)⁺], 91.0 [60, (PhCH₂+H)⁺].

11-Oxo-3 β -benzyloxy-18 β -glycerrythetinic acid**11-Oxo-3 α -hydroxy-18 β -glycerrythetinic acid benzyl ester (DGS01046 D) (16)**

5


R_f : 0.70 (CHCl_3 : methanol = 9 : 1); m.p. : 125 - 126 °C; MS (FAB⁺) m/z : 91.0 [60, $(\text{PhCH}_2+\text{H})^+$], 561.4 [100, $(\text{M}+\text{H})^+$]; Acc. MS (FAB⁺) : 561.3933, $\text{C}_{37}\text{H}_{53}\text{O}_4$ requires 561.3944.

10 **11-Oxo-3 α -benzyloxy-18 β -glycerrythetinic acid****Generation of Diazomethane (DG 336) (17)**

- 15 The mini Diazald apparatus was assembled and the condenser was filled with dry ice and then acetone was added slowly until the cold finger is about one third full. In the reaction vessel, absolute ethanol (95%, 10 ml) was added to a solution of potassium hydroxide pellets (5 g) dissolved in water (8 ml). A receiver flask with a clear seal joint was attached to the condenser and the ether trap at the side arm of the condenser were
- 20 cooled in an ice bath.


The reaction vessel was warmed to 65 °C and the diazald (5g, 23 mmol) dissolved in diethyl ether (45 ml) was added dropwise over a period of 20 mins. The rate of distillation should be approximately equal to the rate of addition. When all of the diazald has been used up, diethyl ether (10 ml) was added slowly and continued with the distillation until the distillate is colourless. The diazomethane (17) was collected as a yellow solution in diethyl ether (700 mg; 16.6 mmol).

Methyl 3-oxo-18 β -glycerrhetate (DGS01082 B) (STX 194) (19)



- 10 Using the procedure described for the preparation of 11, Jones' reagent (1 ml) was added to a solution of 18 β -glycerrhetic acid (100 mg; 0.21 mmol) in acetone (5 ml) and stirred for 30 mins at 0 °C. The crude white solid (94 mg) was purified by preparative TLC (CHCl₃ : Methanol = 9 : 1) to give a white solid (72 mg), which was recrystallised from hot absolute ethanol to give 19 as white crystals (59 mg; 59%). R_f : 0.88 (CHCl₃ : Methanol = 9 : 1); m.p. : 249 – 250 °C; MS (FAB⁺) m/z : 483.2 [100, (M+H)⁺]; MS (FAB⁻) m/z : 481.1 [100, (M-H)⁻].


Methyl 3-deoxo-18 β -glycerrhetate (DGS02018 B) (20)



- 20 Using the procedure described for the preparation of 12, a solution of 19 (40 mg; 0.09 mmol) in acetic acid (5 ml) and PtO₂ (24 mg; 0.11 mmol) were stirred over night at R.T. under an atmosphere of H₂. On evaporation of the solvent, a white solid (43 mg) was obtained, which was purified by preparative TLC (ethyl acetate : hexane = 1 : 1) and the white solid (26 mg) isolated was further purified by recrystallisation from hot absolute ethanol to give 20 as white needles (11 mg; 28%). R_f : 0.61 (ethyl acetate : hexane = 1 : 25


1); m.p. : 234 – 236 °C; MS (FAB⁺) m/z : 469.2 [100, (M+H)⁺]; MS (FAB⁻) m/z : 467.0 [100, (M-H)⁻].

Methyl 11-deoxy-3 β -hydroxy-18 β -glycerrhetate (DG 383 B) (21)



5 Using the procedure described for the preparation of **12**, a solution of **18** (90 mg; 0.19 mmol) in acetic acid (8 ml) and PtO₂ (53 mg; 0.23 mmol) were stirred over night at R.T. under an atmosphere of H₂. On evaporation of the solvent, a white solid (37 mg) was obtained, which was purified by preparative TLC (ethyl acetate : hexane = 1 : 1) and the
 10 white solid (24 mg) isolated was further purified by recrystallisation from hot absolute ethanol to give **21** as white needles (12 mg; 14%). R_f : 0.84 (ethyl acetate : hexane = 1 : 1); m.p. : 291 - 293 °C; MS (FAB⁺) m/z : 471.3 [100, (M+H)⁺]; MS (FAB⁻) m/z : 469.2 [100, (M-H)⁻].


15 **3 β -Hydroxy-11-oxo-18 β -glycyrrhetic acid methyl ester (DGS01056 A) (STX 195) (22)**




A solution of 18 β -glycyrrhetic acid (1 g; 2.12 mmol; 1 equiv.) in anhydrous DMF (50 ml) containing anhydrous K₂CO₃ (2.9 g; 21.2 mmol; 10 equiv.) was stirred at R.T. under N₂
 20 for 1 hour. Methyl iodide (1.45 ml; 23.37 mmol; 11 equiv.) was introduced to the reaction mixture followed by tetra butyl ammonium iodide (200 mg). The resulting mixture was stirred for 24 hours at R.T, poured in to brine and the organics were extracted with ethyl acetate (3×200 ml), washed with H₂O (3×100 ml), dried with MgSO₄, filtered and evaporated under reduced pressure to give a white solid (1.07 g), which was purified by

recrystallisation with hot absolute ethanol to give **22** as white crystals (827 mg; 80%). R_f : 0.67 (CHCl_3 : methanol = 9 : 1); m.p. : 249 - 251 °C (dec.) (Lit. m.p. : 253 - 255 °C); MS (FAB⁺) m/z : 485.3 [100, (M+H)⁺]; MS (FAB⁻) m/z : 483.2 [100, (M-H)⁻].

5 **3 β -Methoxy-11-oxo-18 β -glycerrhetinic acid**





11-Deoxy-3 β -hydroxy-18 β -glycyrrhetinic acid methyl ester (DGS01092 B) (23)





- 10 Using the procedure described for the preparation of **12**, a solution of **22** (100 mg; 0.21 mmol) in acetic acid (10 ml) and PtO_2 (58 mg; 0.26 mmol) were stirred over night at R.T. under an atmosphere of H_2 . On evaporation of the solvent, a white solid (126 mg) was obtained, which was purified by flash chromatography (CHCl_3 /methanol gradient, 10:1 to 6:1) and the white solid isolated (93 mg) was recrystallised with hot absolute ethanol to
- 15 give **23** as white crystals (64 mg; 66%). R_f : 0.67 (CHCl_3 : methanol = 10 : 1); m.p. : 135 - 137 °C; MS (FAB⁺) m/z : 471.3 [100, (M+H)⁺]; MS (FAB⁻) m/z : 469.1 [100, (M-H)⁻].

11-Deoxy-3 β -methoxy-18 β -glycyrrhetinic acid



3 β -hydroxy-11-oxo-18 β -glycyrrhetic acid ethyl ester (DGS01058 A) (STX 196) (24)


Using the procedure described for the preparation of **22**, a solution of 18 β -glycyrrhetic acid (1 g; 2.12 mmol) in DMF (50 ml), K₂CO₃ (2.9 g; 21.2 mmol), ethyl bromide (1.74 ml; 23.37 mmol) and tetra butyl ammonium iodide (200 mg) were stirred for 24 hours at R.T.
 The crude yellow solid (1.11 g) was purified by flash chromatography (CHCl₃/methanol gradient, 10:1 to 6:1) and the white solid isolated (881 mg) was recrystallised with hot absolute ethanol to give **24** as a pale yellow crystals (592 mg; 56%). *R_f*: 0.71 (CHCl₃ : methanol = 9 : 1); m.p.: 93 – 94 °C; MS (FAB⁺) *m/z*: 499.2 [100, (M+H)⁺]; MS (FAB⁻) *m/z*: 497.1 [100, (M-H)⁻].

3 β -Ethoxy-11-oxo-18 β -glycyrrhetic acid**11-Deoxy-3 β -hydroxy-18 β -glycyrrhetic acid ethyl ester (DGS01094 B) (25)**

Using the procedure described for the preparation of **12**, a solution of **24** (100 mg; 0.20 mmol) in acetic acid (8 ml) and PtO₂ (57 mg; 0.25 mmol) were stirred over night at R.T. under an atmosphere of H₂. On evaporation of the solvent, the yellow solid (105 mg) obtained was purified by preparative TLC (ethyl acetate : hexane = 1 : 1) to give a yellow solid (62 mg) and recrystallised from hot absolute ethanol to give **25** as a pale yellow


crystals (41 mg; 42%). R_f : 0.79 (ethyl acetate : hexane = 1 : 1); m.p. : 139 - 141 °C; MS (FAB⁺) m/z : 485.3 [100, (M+H)⁺]; MS (FAB⁻) m/z : 483.1 [100, (M-H)⁻].

11-Deoxy-3 β -ethoxy-18 β -glycyrrhetic acid



5


3 β -hydroxy-11-oxo-18 β -glycyrrhetic acid *tert*-butyl ester (DGS01064 C) (26)




Using the procedure described for the preparation of **22**, a DMF (50 ml) solution of 18 β -glycyrrhetic acid (1 g; 2.12 mmol), K₂CO₃ (2.9 g; 21.2 mmol), 2-bromo-2-methylpropane (2.4 ml; 21.2 mmol) and tetra butyl ammonium iodide (200 mg) were stirred for 24 hours at R.T. The crude yellow solid (2.63 g) was purified by flash chromatography (CHCl₃/methanol gradient, 10:1 to 6:1) and the two yellow solids isolated (264 mg and 171 mg) were recrystallised with hot absolute ethanol to give **26** (201 mg; 18%) and **27** (132 mg; 12%) as yellow crystals. R_f : 0.78 (CHCl₃ : methanol = 9 : 1); m.p. : 171 – 174 °C.

15



3 β -*tert*-butoxy-11-oxo-18 β -glycyrrhetic acid





20

3 α -hydroxy-11-oxo-18 β -glycyrrhetic acid *tert*-butyl ester (DGS01064 D) (27)


R_f : 0.71 (CHCl_3 : methanol = 9 : 1); m.p. : 95 - 97 °C.

5 **3 α -*tert*-butoxy-11-oxo-18 β -glycyrrhetic acid****3 β -hydroxy-11-oxo-18 β -glycyrrhetic acid isopropyl ester (DGS01084 A) (29)**


- 10 Using the procedure described for the preparation of 22, a DMF (60 ml) solution of 18 β -glycyrrhetic acid (1 g; 2.12 mmol), K_2CO_3 (2.9 g; 21.2 mmol), 2-bromo propane (2 ml; 21.25 mmol) and tetra butyl ammonium iodide (200 mg) were stirred for 24 hours at R.T. The crude white solid (1.2 g) obtained was recrystallised with hot absolute ethanol to give 29 as white crystals (622 mg; 58%). R_f : 0.54 (ethyl acetate : hexane = 1 : 1); m.p. :
 15 271 - 273 °C (dec.).

3 β -isopropoxy-11-oxo-18 β -glycerrhetinic acid5 **11-Deoxy-3 β -hydroxy-18 β -glycyrrhetinic acid isopropyl ester (DGS01186 B) (30)**

Using the procedure described for the preparation of 12, a solution of 29 (100 mg; 0.20 mmol) in acetic acid (10 ml) and PtO₂ (55 mg; 0.24 mmol) were stirred over night at R.T. On evaporation of the solvent, a white solid (113 mg) was obtained, which was purified
 10 by flash chromatography (ethyl acetate/hexane gradient, 8:1 to 2:1) and the white solid isolated (75 mg) was recrystallised from hot absolute ethanol to give 30 as white needles (51 mg; 52%). R_f: 0.86 (ethyl acetate : hexane = 1 : 1); m.p. : 201 – 203 °C.


11-Deoxy-3 β -^{iso}propyloxy-18 β -glycyrrhetinic acid

3 β -hydroxy-11-oxo-18 β -glycyrrhetic acid phenylethyl ester (DGS01072 B) (STX 197) (31)




Using the procedure described for the preparation of **22**, a solution of 18 β -glycyrrhetic acid (1 g; 2.12 mmol) in DMF (50 ml), K₂CO₃ (2.9 g; 21.2 mmol), 2-bromoethylbenzene (2.9 ml; 21.2 mmol) and tetra butyl ammonium iodide (200 mg) were stirred for 24 hours at R.T. The crude pale yellow solid (1.15 g) was purified by flash chromatography (ethyl acetate : hexane = 1 : 1) and the white solid isolated (829 mg) was recrystallised with hot absolute ethanol to give **31** as white crystals (792 mg; 65%). R_f : 0.78 (ethyl acetate : hexane = 1 : 1); m.p. : 168 - 169 °C; MS (FAB⁺) m/z : 91.0 [60, (PhCH₂+H)⁺], 575.1 [100, (M+H)⁺].

3 β -Phenethyloxy-11-oxo-18 β -glycyrrhetic acid (STX 197a)



15

11-Deoxy-3 β -hydroxy-18 β -glycyrrhetic acid phenylethyl ester (DGS01172 B) (STX 225) (32)




Using the procedure described for the preparation of **12**, a solution of **31** (100 mg; 0.17 mmol) in acetic acid (10 ml) and PtO₂ (49 mg; 0.22 mmol) were stirred over night at R.T.


20

On evaporation of the solvent, a white solid (114 mg) obtained was purified by flash chromatography (ethyl acetate/hexane gradient, 8:1 to 2:1) and the white solid isolated (91 mg) was recrystallised from hot absolute ethanol to give **32** as white crystals (76 mg; 78%). R_f : 0.82 (ethyl acetate : hexane = 1 : 1); m.p. : 153 - 155 °C; MS (FAB⁺) m/z : 91.0 [70, (PhCH₂+H)⁺], 561.3 [100, (M+H)⁺]; MS (FAB⁻) m/z : 559.2 [100, (M-H)⁻].



11-Deoxy-3 β -phenethyloxy-18 β -glycyrrhetic acid



3 β -hydroxy-11-oxo-18 β -glycyrrhetic acid phenylpropyl ester (DGS01074 C) (33)




Using the procedure previously described for the preparation of **22**, a solution of 18 β -glycyrrhetic acid (1 g; 2.12 mmol) in DMF (50 ml), K₂CO₃ (2.9 g; 21.2 mmol), 1-bromo-3-phenylpropane (3.23 ml; 21.25 mmol) and tetra butyl ammonium iodide (200 mg) were stirred for 24 hours at R.T. The crude yellow solid (1.06 g) obtained was purified by flash chromatography (ethyl acetate/hexane gradient, 8:1 to 2:1) and the two white solids isolated (374 mg and 229 mg) were recrystallised with hot acetone and hot absolute ethanol to give **33** (262 mg; 21%) and **34** as white crystals (198 mg; 16%) respectively. R_f : 0.84 (ethyl acetate : hexane = 1 : 1); m.p. : 171 - 172 °C.


3 β -[3-Phenylpropyl]oxy-11-oxo-18 β -glycerrhetinic acid**3 α -hydroxy -11-oxo-18 β -glycyrrhetinic acid phenylpropyl ester (DGS01074 D) (34)**

5

R_f : 0.78 (ethyl acetate : hexane = 1 : 1); m.p. : 114 - 116 °C.

3 α -[3-Phenylpropyl]oxy-11-oxo-18 β -glycerrhetinic acid

10

11-Deoxy-3 β -hydroxy-18 β -glycyrrhetinic acid phenylpropyl ester (DGS01188 B) (STX 226) (35)


15

Using the procedure previously described for the preparation of **12**, a solution of **33** (100 mg; 0.17 mmol) acetic acid (10 ml) and PtO_2 (48 mg; 0.21 mmol) were stirred over night at R.T. On evaporation of the solvent, the crude white solid (123 mg) was purified by

flash chromatography (ethyl acetate/hexane gradient, 8:1 to 2:1) and the white solid isolated (81 mg) was recrystallised from hot absolute ethanol to give **35** as white needles (67 mg; 68%). R_f : 0.81 (ethyl acetate : hexane = 1 : 1); **m.p.** : 158 - 160 °C; **MS** (FAB⁺) m/z : 91.0 [80, (PhCH₂+H)⁺], 575.2 [100, (M+H)⁺]; **MS** (FAB⁻) m/z : 573.1 [100, (M-H)⁻].


5

11-Deoxy-3 β -[phenylpropyl]oxy-18 β -glycyrrhetic acid





3 β -hydroxy-11-oxo-18 β -glycyrrhetic acid cyclohexyl ester (DGS01062 B) (STX 215) (36)

10




Using the procedure previously described for the preparation of **22**, a solution of 18 β -glycyrrhetic acid (1 g; 2.12 mmol) in DMF (60 ml), K₂CO₃ (2.9 g; 21.2 mmol), cyclohexyl iodide (4.5 ml; 21.25 mmol) and butyl ammonium iodide (200 mg) were refluxed for 2 hours. The crude yellow solid (1.39 g) obtained was purified by flash chromatography (ethyl acetate/hexane gradient, 8:1 to 2:1) and the white solid isolated (540 mg) was recrystallised from hot absolute ethanol to give **36** as white crystals (217 mg; 19%). R_f : 0.63 (ethyl acetate : hexane = 1 : 1); **m.p.** : 213 - 216 °C; **MS** (FAB⁺) m/z : 553.1 [100, (M+H)⁺]; **MS** (FAB⁻) m/z : 551.1 [100, (M-H)⁻].


20

3 β -Cyclohexyloxy-11-oxo-18 β -glycerrhetinic acid**11-Deoxy-3 β -hydroxy-18 β -glycyrrhetinic acid cyclohexyl ester (DGS01112 B) (STX**5 **169) (37)**

Using the procedure previously described for the preparation of **12**, a solution of **35** (100 mg; 0.18 mmol) in acetic acid (10 ml) and PtO₂ (51 mg; 0.23 mmol) were stirred over night at R.T. On evaporation of the solvent, the yellow solid (132 mg) obtained was purified by flash chromatography (ethyl acetate/hexane gradient, 8:1 to 2:1) and the pale yellow solid isolated (74 mg) was recrystallised from hot absolute ethanol to give **37** as pale yellow crystals (48 mg; 49%). R_f: 0.78 (ethyl acetate : hexane = 1 : 1); m.p. : 163 – 166 °C; MS (FAB⁺) m/z : 539.2 [100, (M+H)⁺]; MS (FAB⁻) m/z : 537.1 [100, (M-H)⁻].


15 **11-Deoxy-3 β -cyclohexyloxy-18 β -glycyrrhetinic acid**

3 β -hydroxy-11-oxo-18 β -glycyrrhetic acid cyclohexylmethyl ester (DGS01070 B) (STX 198) (38)




Using the procedure previously described for the preparation of **22**, a DMF (75 ml) solution of 18 β -glycyrrhetic acid (1 g; 2.12 mmol), K₂CO₃ (2.9 g; 21.25 mmol), bromomethyl cyclohexane (3 ml; 21.25 mmol) and tetra butyl ammonium iodide (200 mg) were refluxed for 2 hours. The crude yellow solid (1.72 g) obtained was purified by flash chromatography (ethyl acetate/hexane gradient, 8:1 to 2:1) and the white form isolated (1.05 g) was recrystallised with hot absolute ethanol to give **38** as white crystals (703 mg; 59%). *R*_f: 0.81 (ethyl acetate : hexane = 1 : 1); m.p. : 98 - 99 °C; MS (FAB⁺) *m/z* : 567.2 [100, (M+H)⁺]; MS (FAB⁻) *m/z* : 565.1 [100, (M-H)⁻].

3 β -cyclohexylmethoxy-11-oxo-18 β -glycyrrhetic acid



15

11-Deoxy-3 β -hydroxy-18 β -glycyrrhetic acid cyclohexylmethyl ester (DGS01184 B) (STX 227) (39)




Using the procedure previously described for the preparation of **12**, a solution of **38** (100 mg; 0.18 mmol) in acetic acid (10 ml) and PtO₂ (50 mg; 0.22 mmol) were stirred over night at R.T. On evaporation of the solvent, the yellow solid (114 mg) obtained was

20

purified by flash chromatography (ethyl acetate/hexane gradient, 8:1 to 2:1) and the pale yellow solid isolated (72 mg) was recrystallised with hot absolute ethanol to give **39** as fine white crystals (59 mg; 59%). R_f : 0.79 (ethyl acetate : hexane = 1 : 1); m.p. : 133 - 134 °C; MS (FAB⁺) m/z : 553.2 [100, (M+H)⁺]; MS (FAB⁻) m/z : 551.3 [100, (M-H)⁻].

5


3 β -Acetyloxy-18 β -glycyrrhetic acid (DGS0110 A) (40)



A mixture of 18 β -glycyrrhetic acid (1 g; 2.12 mmol), acetic anhydride (1 ml; 10.62 mmol) and pyridine (15 ml) were stirred under reflux for 2 hr. The cooled reaction mixture was concentrated in vacuo and then quenched with ice-water (100 ml). The crude white precipitate formed (1.28 g) was filtered out and washed with plenty of water and the vacuum dried solid was recrystallised with hot absolute ethanol to give **40** as fine white crystals (961 mg; 88%). R_f : 0.56 (ethyl acetate : hexane = 1 : 1); m.p. : 298 – 299 °C; MS (FAB⁺) m/z : 513.2 [100, (M+H)⁺]; MS (FAB⁻) m/z : 511.4 [100, (M-H)⁻]; Acc. MS m/z (FAB⁺) : 513.3475, C₃₂H₄₉O₅ requires 512.3202.


15

O-Alkylation of the Methyl-ester of glycyrrhetic acid



20


Experimental



5 R = Benzyl STX359


To a solution of Glycyrrhetic acid methyl ester (0.200 g, 0.000413 mol) in freshly distilled THF (5.0 ml) under nitrogen atmosphere at room temperature was added sodium hydride (0.036 mg, 0.000826 mol; 60% dispersed in mineral oil), followed by
10 benzyl bromide (0.105 g, 0.000619 mol). The reaction mixture was stirred at room temperature for about 1 h, and refluxed at 64 °C for approximately 40 hours. Once the reaction had gone to completion (monitored by tlc), the crude mixture was cooled to room temperature and quenched by drop wise addition of water over 20 min. The aqueous layer was extracted with ethyl acetate, washed with brine, dried (MgSO₄) and
15 concentrated under reduced pressure to give a pale yellow solid. The resulting crude product was purified by flash chromatography (EtOAc: hexane, gradient elution) to afford the benzylated product as a colourless solid (0.120 g, 51%); Diagnostic signals of ¹H NMR (CDCl₃) δ 7.35-7.32 (multiplet, 5H, phenyl), 5.66 (s, 1H, olefinic), 4.69 (d, *J* = 12.2 Hz, 1H, aromatic), 4.40 (d, *J* = 11.7 Hz, 1H, aromatic), 3.69 (s, 3H, OMe), 2.94 – 2.84
20 (dd, *J* = 7.4 and 11.7 Hz, 1H, CH), 2.83 – 2.80 (broad dt, 1H, CH), 2.32 (s, 1H, CH), 2.09-1.58 (multiplet, ring H), 1.56 (sharp s, H₂O), 1.41-1.38 (broad multiplet, ring H), 1.35 (s, 3H, Me), 1.32-1.19 (broad m, ring H), 1.15 (s, 3H, Me), 1.14 (s, 3H, Me), 1.12 (s, 3H, Me), 1.00 (s, 3H, Me), 0.86 (s, 3H, Me), 0.80 (s, 3H, Me); HPLC: *R_T* = 3.57 (85%); MP = 285 °C.

25



***R* = Methyl HDS01028A (STX400)**


This compound was synthesised using the same experimental procedure as shown for
 5 benzyl derivative (See above); Diagnostic signals of ^1H NMR (CDCl_3) δ 5.67 (s, 1H, olefinic), 3.69 (s, 3H, OMe), 3.36 (s, 3H, Me), 2.84 – 2.81, (broad dt, 1H, CH), 2.69 (dd, J = 4.7 and 11.7 Hz, 1H, CH) 2.33 (s, 1H, CH), 2.09-1.58 (multiplet, ring H), 1.56 (sharp s, H_2O), 1.41-1.38 (broad multiplet, ring H), 1.36 (s, 3H, Me), 1.32-1.19 (broad m, ring H), 1.15 (s, 3H, Me), 1.14 (s, 3H, Me), 1.12 (s, 3H, Me), 0.99 (s, 3H, Me), 0.81 (s, 3H, Me),
 10 0.79 (s, 3H, Me); HPLC: R_T = 5.63 (> 90%)



***R* = 3-Methoxy benzyl HDS01028D (STX401)**

15 This compound was synthesised using the same experimental procedure as shown for benzyl derivative (See above); Diagnostic signals of ^1H NMR (CDCl_3) δ 7.23 (d, J = 8 Hz, Aromatic H), 6.94 (app d, aromatic H), 6.92 (overlapping s, 1H, aromatic H) 6.82 (d, J = 2.0 Hz, aromatic H), 6.81 (d, J = 5.0 Hz, aromatic H) 5.66 (s, 1H, olefinic), 4.67 (d, J = 12 Hz, 1H, benzylic), 4.41 (d, J = 12.2 Hz, 1H benzylic), 3.81 (s, 3H, OMe), 3.69 (s, 3H, OMe), 2.96 – 2.92 (dd, J = 4.3 and 11.7 Hz, 1H, CH), 2.83 – 2.80, (broad dt, 1H, CH), 2.33 (s, 1H, CH), 2.09-1.58 (multiplet, ring H), 1.56 (sharp s, H_2O), 1.41-1.38 (broad multiplet, ring H), 1.36 (s, 3H, Me), 1.32-1.19 (broad m, ring H), 1.16 (s, 3H, Me), 1.15 (s,
 20


3H, Me), 1.13 (s, 3H, Me), 1.01 (s, 3H, Me), 0.87 (s, 3H, Me), 0.81 (s, 3H, Me); HPLC: R_T = 5.03 (> 98%)



5 ***R* = *para* Tert-butyl benzyl STX360**

This compound was synthesised using the same experimental procedure as shown for benzyl derivative (See above); Diagnostic signals of ^1H NMR (CDCl_3) δ 7.97 (d, J = 7.8 Hz, 2H, aromatic), 7.46 (d, J = 4.7 Hz, 2H, aromatic) 5.66 (s, 1H, olefinic), 4.65 (d, J = 11.7 Hz, 1H, benzylic H), 4.39 (d, J = 11.8 Hz, 1H, benzylic H), 3.69 (s, 3H, OMe), 2.96 – 2.82 (dd, J = 4.3 and 11.3 Hz, 1H, CH), 2.84 – 2.80 (broad dt, 1H, CH), 2.32 (s, 1H, CH), 2.09-1.58 (multiplet, ring H), 1.56 (sharp s, H_2O), 1.41-1.38 (broad multiplet, ring H), 1.36 (s, 3H, Me), 1.32-1.19 (broad m, ring H), 1.15 (s, 3H, Me), 1.14 (s, 3H, Me), 1.12 (s, 3H, Me), 1.01 (s, 3H, Me), 0.86 (s, 3H, Me), 0.80 (s, 3H, Me); HPLC: R_T = 4.97 (85%)

15 **Synthesis of glycyrrhetic acid amide derivatives**



R_1 = OH, OAc,


R_2 = H, R_3 = CH_2Ph ; R_2 = H, R_3 = $\text{CH}(\text{CH}_3)\text{COOC}_2\text{H}_5$; R_2 = H, R_3 = $\text{CH}(\text{CH}_3)\text{COOH}$;
 R_2 = H, R_3 = cyclopropane; R_2 = H, R_3 = 2-methylpyridine; R_2 = H, R_3 = 2-(4-ethylmorpholine);
 R_2R_3 = piperidine; R_2 = H, R_3 = $\text{CH}_2(\text{CH}_2)_4\text{OH}$

Method A

To a solution of the acid (0.2 mmol) in chloroform (5 ml) was added amine (0.4 mmol) and EDCI (0.4 mmol). The mixture was stirred under nitrogen at room temperature for 6 to 16 hours. TLC showed the completion of the reaction. The reaction mixture was poured into water, extracted with dichloromethane. The organic phase was washed with 2% HCl and water, dried over MgSO₄. Evaporation of the solvent gave a residue, which was purified by flash chromatography. The yield was between 30 to 80%. The product was characterised by NMR, MS, Hi Res-MS, TLC and HPLC.

Method B

To a solution of the acid (0.5 mmol) in dichloromethane (15 ml) was added amine (1.0 mmol), HOBt (0.26 mmol), EDCI (0.55 mmol), DMAP (0.55 mmol) and triethylamine (0.55 mmol). The mixture was stirred under nitrogen at room temperature for 16 to 24 hours. TLC showed the completion of the reaction. The reaction mixture was poured into water, extracted with dichloromethane. The organic phase was washed with 2% HCl and water, dried over MgSO₄. Evaporation of the solvent gave a residue, which was purified by flash chromatography. The yield was between 60 to 90%. The product was characterised by NMR, MS, Hi Res-MS, TLC and HPLC.

18 β -glycyrrhetic acid benzylamide STX 366 (XDS01030)

To a solution of the glycyrrhetic acid (100 mg, 0.213 mmol) in chloroform (5 ml) was added benzylamine (0.05 ml, 0.458 mmol) and EDCI (98 mg, 0.511 mmol). The mixture was stirred under nitrogen at room temperature for 6 hours. TLC showed the completion

of the reaction. The reaction mixture was poured into water, extracted with dichloromethane. The organic phase was washed with 2% HCl and water, dried over MgSO₄. Evaporation of the solvent gave a residue, which was purified by flash chromatography to give off-white powder (40 mg, 33%).


5 TLC (5% Methanol-dichloromethane) single spot at R_f 0.75.

HPLC t_R 2.58 min, purity 98%

¹HNMR 400MHz CDCl₃ 7.26-7.37 (m, 5H, aromatic protons), 5.83 (t, 1H, NH), 5.57(s, 1H, 12-H), 4.47(m, ABX, 2H, NHCH₂Ph), 3.21(dt, 1H, 3 α -H), 2.78(dt, 1H, 18-H), 2.31(s, 1H, 9 α -H).

10 MS(FAB+)m/z: 560(100, M+1)

3 β -Acetoxy-18 β -glycyrrhetic acid benzylamide STX367 (XDS01031B)



15


The compound was synthesised with general method A.

TLC (25% Ethyl acetate-Hexane) single spot at R_f 0.85.

HPLC t_R 3.57 min, purity 97.7%

20 ¹HNMR 400MHz CDCl₃ 7.29-7.52 (m, 5H, aromatic protons), 5.83 (t, 1H, NH), 5.56(s, 1H, 12-H), 4.51(dt, 1H, 3 α -H), 4.47(m, ABX, 2H, NHCH₂Ph), 2.78(dt, 1H, 18-H), 2.33(s, 1H, 9 α -H), 2.05(s, 3H, 3-CH₃CO-)

MS(FAB+)m/z: 602(100, M+1)

18 β -glycyrrhetic acid L-alanine ethyl ester amide STX369 (XDS01034)

The compound was synthesised with general method B.


5 TLC (5% Methanol-dichloromethane) single spot at R_f 0.68.

HPLC t_R 4.21 min, purity 99%

^1H NMR 400MHz CDCl_3 6.14 (d, 8Hz, 1H, NH), 5.76(s, 1H, 12-H), 4.60(dq, 1H, NHCH), 4.23(q, 2H, -OCH₂CH₃), 3.23(dt, 1H, 3 α -H), 2.82(dt, 1H, 18-H), 2.34(s, 1H, 9 α -H).

MS(FAB+) m/z : 570(100, $M+1$)

10

18 β -glycyrrhetic acid cyclopropylamide STX370 (XDS01035)

The compound was synthesised with general method B.


15 TLC (5% Methanol-dichloromethane) single spot at R_f 0.70.

HPLC t_R 3.89min, purity 99%

^1H NMR 400MHz CDCl_3 5.64 (d, 2H, NH and 12-H), 3.23(dt, 1H, 3 α -H), 2.82(dt, 1H, 18-H), 2.71(m, 1H, -NHCH), 2.34(s, 1H, 9 α -H).

MS(FAB+) m/z : 510(100, $M+1$)

20

18 β -glycyrrhetic acid (pyridin-2-ylmethyl)-amide STX371 (XDS01036)


5 The compound was synthesised with general method B.

TLC (5% Methanol-dichloromethane) single spot at R_f 0.45.

HPLC t_R 3.69min, purity 95%

^1H NMR 400MHz CDCl_3 8.68 (dd, 1H, 6'-H of pyridine), 7.68(td, 1H, 4'-H of pyridine),
7.36(t, 1H, NH), 7.22-7.28(m, 2H, 3',5'-H of pyridine), 5.91 (s, 1H, 12-H), 4.59(m, ABX,
10 2H, NHCH₂Py), 3.23(dt, 1H, 3 α -H), 2.83(dt, 1H, 18-H), 2.38(s, 1H, 9 α -H).

MS(FAB+)m/z: 561(100, M+1)

18 β -glycyrrhetic acid (2-morpholin-4-yl-ethyl)-amide STX372 (XDS01037)

15

The compound was synthesised with general method B.

TLC (5% Methanol-dichloromethane) single spot at R_f 0.52.


HPLC t_R 3.92min, purity 97%

^1H NMR 400MHz CDCl_3 : 6.21(t, 1H, NH), 5.71 (s, 1H, 12-H), 3.72(m, 4H, $-(\text{CH}_2)_2\text{O}$ of morpholine), 3.38(m, 2H, $-\text{CONHCH}_2-$), 3.23(dt, 1H, 3 α -H), 2.82(dt, 1H, 18-H), 2.20-2.40(m, 6H, $-\text{CH}_2\text{N}(\text{CH}_2)_2$).

MS(FAB+) m/z : 583(100, M+1)

5

18 β -glycyrrhetic acid piperidine-amide (XDS01038)




10 The compound was synthesised with general method B.

TLC (5% Methanol-dichloromethane) single spot at R_f 0.70.

^1H NMR 400MHz CDCl_3 : 5.71 (s, 1H, 12-H), 3.55(m, 4H, $-\text{N}(\text{CH}_2)_2$ of piperidine), 3.23(dt, 1H, 3 α -H), 2.82(dt, 1H, 18-H), 2.35(s, 1H, 9 α -H).

15 **18 β -glycyrrhetic acid (5-hydroxy-pentyl)-amide (XDS01039)**



20 The compound was synthesised with general method B.

TLC (5% Methanol-dichloromethane) single spot at R_f 0.70.

^1H NMR 400MHz CDCl_3 : 5.67 (s, 1H, 12-H), 5.63(t, 1H, NH), 3.68(dt, 2H, $-\text{NHCH}_2-$),

3.34(m, 2H, $-\underline{\text{CH}_2}\text{OH}$), 3.23(dt, 1H, 3 α -H), 2.80(dt, 1H, 18-H), 2.38(s, 1H, 9 α -H).

Methods

Synthesis of radio labelled cortisone

5

Labelled cortisone is commercially not available. Therefore labelled cortisol (F) (^3H -F and ^{14}C -F) was oxidised at the C-11 position with CrO_3 in order to synthesize to the corresponding labelled cortisone (^3H -E and ^{14}C -E).

- 10 For this reaction F was oxidised in a 0,25% CrO_3 (w/v) dissolved in a 50% acetic-acid/distilled water (v/v) solution. The labelled F was then added to 1 ml of the CrO_3 solution, vortex mixed and put in an incubator for 20 minutes at 37°C. The aqueous reaction mixture was extracted twice with 4 ml of di-ethylether, the di-ethylether was then evaporated and the residue transferred to a TLC-plate, which was developed in the
- 15 following system, chloroform : methanol 9:1 (v/v). Unlabelled cortisone (E) was also run on the TLC-plate to locate the position of the labelled steroids. After locating the spot of the labelled steroids this area is cut out from the TLC-plate and eluted with 0,5 ml of methanol.

20 The amount of protein per μL of rat liver and rat kidney

- The amount of protein in rat liver and rat kidney needed to be determined. The experiment was done according to the Bradford method [15]. The following method was used: first a BSA (protein) solution was prepared (1 mg/ml). Protein solutions containing
- 25 10 to 100 μg protein were pipetted into tubes and volumes adjusted with distilled water. Then 5 ml of protein reagent was added to the tubes and vortex mixed. The absorbance was measured at 595 nm after 15 minutes and before 1 hour in 3 ml cuvettes against a reagent blank. The weight of the protein was plotted against the corresponding absorbance resulting in a standard curve used to determine the protein concentration in
- 30 rat liver and rat kidney cytosols.

Assay validation - Enzyme concentration and time-dependency of 11 β -HSD activity

- 35 Before carrying out 11 β -HSD assays to examine the conversion E to F and F to E and

the influence that different inhibitors have on these conversions the amount of rat liver homogenate and rat kidney homogenate and their incubation time need to be determined.

- 5 11 β -HSD type 1 is the enzyme responsible for the conversion E to F and this type of enzyme is present in rat liver. The substrate solution used in this assay contained 70,000 cpm/ml ^3H -E in PBS-sucrose and 0.5 μM of unlabelled E and co-factor NADPH (9 mg/10 ml of substrate solution). 1 ml of the substrate solution and the different amounts of rat liver homogenate was added to all tubes.

10

- The amount of rat liver homogenate needed for an assay was determined by incubating the substrate solution with 25, 50, 100 and 150 μL for 30, 60, 90 and 120 minutes at 37°C in a water bath with the tubes being mechanically shaken. After the incubation 50 μL of recovery solution was added, containing about 8,000 cpm/ 50 μL of ^{14}C -F and 50 μg /50 μL of unlabelled F for visualising the spot on the TLC-plate, to correct for the losses made in the next two steps. F was then extracted from the aqueous phase with 4 ml of ether (2 x 30 sec cycle, vortex mix). The aqueous phase was then frozen using dry-ice and the organic layer was decanted and poured into smaller tubes and evaporated. 6 drops of ether were then added to the small tubes to re-dissolve the residue which was transferred to an aluminium thin layer chromatography plate (TLC-plate). The TLC-plate was developed in a TLC tank under saturated conditions. The solvent system used was chloroform : methanol 9:1 (v/v). The F spots on the TLC-plate were visualised under UV-light and cut out from the TLC-plate ($R_f=0.45$). The spots from the TLC- plate were then put into scintillation vials and 0.5 ml of methanol was added to all vials to elute the radioactivity from the TLC-plate for 5 minutes. 10 ml of Ecoscint was added to the scintillation vials and they were put into the scintillation counter to count amount of product formed.
- 15
20
25

- The same procedure was used for the 11 β -HSD type 2 assay, the conversion F to E, to determine the amount of rat kidney to be used and the incubation time. Except this time the substrate solution contained ^3H -F and unlabelled F and the recovery contained ^{14}C -E and unlabelled E and cortisone has a R_f value of 0.65 on the TLC-plate.
- 30

Assay procedure - The 11 β -HSD inhibitors

In these assays the influence of different inhibitors on the 11 β -HSD activity both in reductive (type 1) and oxidative (type 2) directions were assessed. In the reductive direction E is the substrate and F the product and visa versa in the case of oxidation. The method described here is for the oxidative direction.

The substrate solution contained about 50,000 cpm/ml ^3H -F in PBS-sucrose and 0.5 μM F. 1ml of the substrate solution was added to each tube, the inhibitors were also added, at a 10 μM concentration, to each tube except to the "control" and "blank" tubes. 150 μL was added to all tubes except to the blanks, this was done to correct for the amount of ^3H -F spontaneously formed. The tubes were incubated for 60 minutes in a mechanically shaken water bath at 37°C. The amount of kidney liver homogenate and incubation time used resulted from the enzyme- and time-dependency assay. After incubation 50 μL of recovery was added to correct for the losses made in the next steps, containing 5000 cpm/50 μL of ^{14}C -E and 50 μg /50 μL of unlabelled E (to visualise the spot on the TLC-plate). The aqueous mixture was then extracted with 4 ml of ether (2 x 30 sec cycle, vortex mix). After freezing the aqueous phase, the ether (upper) layer was decanted into smaller tubes and evaporated at 45°C until completely dry. The residue was then re-dissolved in 6 drops of ether and transferred to a TLC-plate. The TLC-plate was developed in chloroform : methanol (9:1 v/v) solvent system, the TLC-plate ran for about 90 minutes until the solvent front had moved about 18 cm. The position of the product E was visualised under UV-light and cut out from the TLC-plate and put into scintillation vials. Radioactivity was eluted over 5 minutes with 0.5 ml methanol. 0.5 ml of PBS-sucrose and 10 ml of Ecoscint were then added and vortex mixed before counting in the scintillation counter. Before counting the samples, two total activity vials were prepared. These contained 0.5 ml of the substrate solution, 50 μL of the recovery, 0.5 ml of methanol and 10 ml of Ecoscint. These two total activity vials were needed to determine the amount of ^{14}C -E and ^3H -F added in the beginning to make the calculations.

30

In case of the reductive direction, E to F, the same method was used. Only the substrate solution containing ^3H -E and unlabelled E and the recovery containing ^{14}C -F and unlabelled F are different to the method used in the oxidative direction.

35 After testing all the inhibitors at 10 μM a dose-response experiment was done for the

most potent 11 β -HSD type 1 and type 2 inhibitors. To look at the percentage of inhibition four different concentrations, 1, 5, 10 and 20 μ M, were used. The method for both the rat liver, type 1 the reductive, and rat kidney, type 2 the oxidative, stay the same throughout the entire experiment.

5

RESULTS

The amount of protein per μ L of rat liver and rat kidney

An initial experiment was carried out to determine the amount of protein in rat liver
10 cytosol and rat kidney cytosol, to be added to each tube. Graph 1 shows the standard curve from which the amount of protein used in both experiments was calculated. The amount of protein added to each tube in the rat liver experiment was 75.5 μ g (per 25 μ L). In the rat kidney experiment the amount of protein added to each tube was 135.6 μ g (per 150 μ L).

15

Enzyme concentration and time-dependency of 11 β -HSD activity

In this experiment the amount of rat liver homogenate and rat kidney homogenate added to each tube and the incubation time was determined. Graph 2 shows the enzyme
20 concentration and time-dependency course of the rat liver experiment E to F, 11 β -HSD type 1 activity. Graph 3 shows the enzyme concentration and time-dependency course F to E, 11 β -HSD type 2 activity. After drawing the graphs the optimal amount of rat liver cytosol and rat kidney cytosol and both their incubation times were selected. One important rule when selecting both variables, to select an amount of rat liver and rat
25 kidney and incubation time on a linear part of the graph. This is done to avoid fluctuations in enzyme activity. The amount of rat liver cytosol selected was 25 μ L and 90 minutes of incubation time, the amount of rat kidney cytosol selected was 150 μ L and 60 minutes of incubation time.

30 The 11 β -HSD inhibitors

In this experiment the influence of different inhibitors on the conversion E to F and F to E was determined. The reason why inhibition in both directions was examined was to make a comparison between the inhibitors and which type of 11 β -HSD they inhibit more.





Thirty-two compounds were screened for their ability to inhibit 11 β -HSD type 1 (E to F) and type 2 (F to E). All the inhibitors were initially tested at a 10 μ M concentration. Their inhibitory effects on the conversion E to F are shown in graphs 4-6 and their inhibitory effects on the conversion F to E are shown in graphs 7-9. The percent of inhibition was
5 calculated as the percentage of decrease in radio labelled ^3H -E and ^3H -F of product formed, compared with the control activity (the tubes without an inhibitor in it). All the results calculated are means, n=2.





The most potent inhibitors were screened at four different concentrations, 1, 5, 10 and
10 20 μ M, to further determine the inhibitory effect of these compounds. The dose response curve of the most potent 11 β -HSD type 1 inhibitors are shown in graph 10. Graph 11 shows a dose response of three potent 11 β -HSD type 2 inhibitors.





Three main groups of structures were selected for investigation. These were:
15 Glycyrrhetic acid derivatives, steroidal compounds and a mixed-group. In table 1, the structures of the inhibitors from the glycyrrhetic acid derivative group are drawn and their percent of inhibition on the conversion E to F and F to E is shown. The same was done for the steroidal compounds in table 2. The inhibition of 11 β -HSD type 1 by the glycyrrhetic acid derivatives ranged from 22% for BLE99006 to 87% for BLE99005.
20 The inhibition of 11 β -HSD type 1 by the steroid group ranged from 14% for DG 316 B to 73% for progesterone.






The inhibition of 11 β -HSD type 2 was also examined all inhibitors were divided into the same groups. For the glycyrrhetic acid derivatives the inhibition ranged from 33% for
25 STX-198 to 100% for BLE 99005, DG 320A, 18 α -glycyrr. Acid, 18 β -glycyrr. Acid and carbenoxalone. The steroid group ranged from 1% stimulation for deoxycholic acid to 84% inhibition for DG 322B.






Table 1 - The Inhibitory Effect of Glycyrrhetic Acid Derivatives





COMPOUND (10 μ M)			% INHIBITION	
CODE	NAME	STRUCTURE	E \rightarrow F \pm SD	F \rightarrow E \pm SD
DG 381A (STX122)			92.67 \pm 1.23	109.03 \pm 1.64
BLE99005			86,9 \pm 0,882	100 \pm 3,566
STX353 18- α -GA	3 β -Hydroxy-11-oxo- 18 α ,20 β -olean-12-en-29-oic acid 18 α -Glycyrrhetic acid		89.05 \pm 1.49	100.47 \pm 0.42
BLE99006	3-Oxo-oleanoic acid		22,2 \pm 0,354	45,6 \pm 11,030




COMPOUND (10 μ M)			% INHIBITION	
CODE	NAME	STRUCTURE	E \rightarrow F \pm SD	F \rightarrow E \pm SD
	Carbenoxalone (disodium salt)		52.2 \pm 4,799	100 \pm 4,161
18- β -GA STX352	3 β -Hydroxy-11-oxo- 18 β ,20 β -olean-12-en-29- oic acid 18 β -Glycyrrhetic acid		85.17 \pm 3.69	101.01 \pm 0.91
STX194 (DGS01082B)			65.79 \pm 5.69	75.05 \pm 2.93
STX195 DG 334B STX121 DG 334A (DGS01056A)			85.43 \pm 2.29	105.21 \pm 1.55

COMPOUND (10 μ M)			% INHIBITION	
CODE	NAME	STRUCTURE	E \rightarrow F \pm SD	F \rightarrow E \pm SD
STX196 (DGS01058A)			80.65 \pm 2.14	97.52 \pm 1.37
STX195a (DGS01056A)			53.0 \pm 1.023	90.3 \pm 1.979
STX196a (DGS01058A)			55.0 \pm 0.022	93.9 \pm 1.767
STX197 (DGS01072A)			53.0 \pm 0.935	59.7 \pm 7.990

COMPOUND (10 μ M)			% INHIBITION	
CODE	NAME	STRUCTURE	E \rightarrow F \pm SD	F \rightarrow E \pm SD
STX198 (DGS01070A)			52.3 \pm 1,253	33.1 \pm 1,838
STX 296			37.74 \pm 8.85	33.76 \pm 15.82
STX 297			34.34 \pm 8.26	58.70 \pm 10.41
STX 298***			50.59 \pm 4.43	22.59 \pm 12.90
STX 299			20.24 \pm 1.89	19.54 \pm 1.66

COMPOUND (10 μ M)			% INHIBITION	
CODE	NAME	STRUCTURE	E \rightarrow F \pm SD	F \rightarrow E \pm SD
STX 347 DG 320A			89.37 \pm 0.10	102.26 \pm 1.28
STX 348			63.39 \pm 1.45	94.77 \pm 0.17
STX 349			89.68 \pm 4.90	100.05 \pm 0.49
STX 350			13.41 \pm 9.63	60.34 \pm 3.99
STX 351			70.02 \pm 6.39	94.41 \pm 0.63

COMPOUND (10 μ M)			% INHIBITION	
CODE	NAME	STRUCTURE	E \rightarrow F \pm SD	F \rightarrow E \pm SD
STX 354			-1.18 \pm 9.22	13.60 \pm 1.42
STX 359			17.8 \pm 2.5	17.0 \pm 3.5
STX 360			14.7 \pm 2.4	26.4 \pm 11.6
STX 366			85.25 \pm 1.09	74.19 \pm 10.34

COMPOUND (10 μ M)			% INHIBITION	
CODE	NAME	STRUCTURE	E \rightarrow F \pm SD	F \rightarrow E \pm SD
STX 367			36.17 \pm 3.69	27.26 \pm 2.99
STX 369			24.91 \pm 2.51	35.38 \pm 12.60
STX 370			89.63 \pm 1.18	102.52 \pm 0.22









COMPOUND (10 μ M)			% INHIBITION	
CODE	NAME	STRUCTURE	E \rightarrow F \pm SD	F \rightarrow E \pm SD
STX 371			57.15 \pm 5.60	92.97 \pm 2.75
STX 372			19.35 \pm 7.81	65.85 \pm 20.91

Table 2 – The Inhibitory effect of Progesterone and Derivatives thereof


COMPOUND (10 μ M)			% INHIBITION	
CODE	NAME	STRUCTURE	E \rightarrow F \pm SD	F \rightarrow E \pm SD
STX125 (DG326B)	Progesterone-3 β ,11 α ,20 β -triol		85.1 \pm 3.4	72.2 \pm 4.3
DG322B	11-hydroxy-Progesterone		32.6 \pm 3.748	83.8 \pm 0.071

COMPOUND (10 μ M)			% INHIBITION	
CODE	NAME	STRUCTURE	E \rightarrow F \pm SD	F \rightarrow E \pm SD
STX-126 ^a (DG354B)			33,8 \pm 0,354	13,5 \pm 2,969
STX-123 (DG375B)			45,7 \pm 8,95	55,2 \pm 1,8
11-keto-P ^a STX124 DG322A	11-keto-Progesterone		100 \pm 6,8	92,6 \pm 2,1
STX 185 DG316B	11 α -Benzylprogesterone		16,1 \pm 10,4	18,9 \pm 4,2
	Deoxycholic acid		27,6 \pm 7,848	-1,1 \pm 8,273
11- β -OH-A ^a	11 β -OH-Androstenedione		55,2 \pm 0,260	40,9 \pm 4,666
P ^a	Progesterone		73,0 \pm 8,955	68,5 \pm 0,707


COMPOUND (10 μ M)			% INHIBITION	
CODE	NAME	STRUCTURE	E \rightarrow F \pm SD	F \rightarrow E \pm SD
F	Cortisol		49,6 \pm 5,866	54,7 \pm 4,243
	Deoxycorticosterone		70,2 \pm 1,655	53,3 \pm 1,273
	Pregnenolone		49,8 \pm 9,355	42,1 \pm 0,777
STX193 (DG357B)	11 α -methoxy-progesterone		48,1 \pm 0,313	68,2 \pm 3,676

All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in chemistry or related fields are intended to be within the scope of the following claims.

APPENDIX I



73



R = CH_3
Et
 tBu
 iPr
 CH_2Ph
 $(\text{CH}_2)_2\text{Ph}$
 $(\text{CH}_2)_3\text{Ph}$
Cyclohexyl
 $\text{CH}_2\text{Cyclohexyl}$

REFERENCES

1. Hammond, GH (1990) : Molecular properties of corticosteroid binding globulin and sex-steroid binding proteins. *Endocr. Rev.* 11, 65- 79.
- 5 2. Gomez-Sanchez EP, Gomex-Sanchez CE (1997): First there was one, then two ..why not more 11 β -Hydroxysteroid Dehydrogenases? *Endocrinology* vol. 138, 12.
3. Krozowski ZS, Funder JW (1983): Renal mineralocorticosterone receptors and hippocampal corticosterone binding species have identical intrinsic steroid specificity . *Proc. Natl. Sci. USA* 80: 6056-60
- 10 4. Ulick S, Levine LS, Gunczler P, Zanconato G, Rarnirez LC, Rauh W, Rosler A, Bradlow HL, Mew MI (1979): A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. *J. Clin. Endo. And Metab.* 49: 757-64.
5. Edwards CRW, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, Kloet ER,
- 15 6. Monder C (1998): Localisation of 11 β -HSD-tissue specific protector of the mineralocorticoid receptor. *Lancet* 2: 986-989.
6. Moore CCD, Melloh SH, Murai I, Siiteri PK, Miller WL (1993): Structure and function of the hepatic form of 11 β -HSD in the squirrel monkey, an animal model of glucocorticoid resistance. *Endocrinology* 133: 368-375.
- 20 7. Kotelevtsev YV, Iarnieson PM, Best R, Stewart F, Edwards CRW, Seckl JR, Mullins // (1996): Inactivation of 11 β -HSD type 1 by gene targeting in mice. *Endocrinology Res.* 22: 791-792.
8. Ricketts ML, Verhaeg JM, Bujalska I, Howie AJ, Rainey WE, Stewart PM (1998): Immunohistochemical localisation of type 1 11 β -HSD in human tissues. *J. Clin. Endoc.*
- 25 9. Metab. 83: 1325-35.
9. Stewart PM, Sheppard MC (1992): Novel aspects of hormone action: intracellular ligand supply and its control by a series of tissue specific enzymes. *Molecular and Cellular Endocrinology* 83: C13-C18.
10. Seckl JR, Chapman KE (1997): The 11 β -HSD system, a determinant of
- 30 glucocorticoid and mineralocorticoid action. Medical and physiological aspects. *European J. Biochem.* 249: 361-364.
11. Maser E (1998): 11 β -HSD responsible for carbonyl re'duction of the tobacco-specific nitrosoamine in mouse lung microsomes. *Cancer Res.* 58: 2996-3003.
12. Walker BR, Stewart PM, Shackleton C H L, Padfield PL, Edwards CRW (1993):
- 35 Deficient inactivation of cortisol by 11 β -HSD in essential hypertension. *Clin. Endocr.*

38: 221-227.

13. Daynes RA, Araneo BA (1998) : Contrasting effects of glucocorticoids on the capacity of T -cells to produce the growth factors interleukin-2 and interleukin-4. Eur. J. Immunol. 19: 2319-2324.


5 14. Bradford MM (1976): A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.

15. Diederich S, Grossmann C, Hanke B, Quinkler M, Herrmann M, Bahr V, Oelkers W (2000): In the search for specific inhibitors of human 11 β -HSD: chenodeoxycholic acid
10 selectively inhibits 11 β -HSD type 1. Europ. J. Endocrin. 142: 200-207.

CLAIMS

1. Use of a compound in the manufacture of a medicament to inhibit 11 β -HSD activity, wherein the compound is selected from glycyrrhetic acid derivatives, progesterone and
5 progesterone derivatives.

2. Use according to claim 1 where the compound is of formula I or a salt thereof



Formula I


wherein R1 is selected from H, alkyl, cycloalkyl, alkenyl, aryl, =O, OH, O-alkyl, O-acyl and O-aryl;

- 10 and R2 is selected from H, =O, OH, hydrocarbyl, oxyhydrocarbyl, and halo;

R5 to R9 are independently selected from H and hydrocarbyl;

R3 and R4 together represent

- (i) a group of formula II




Formula II

wherein R10 is selected from OH, hydrocarbyl, N-hydrocarbyl and O-hydrocarbyl;

- 15 wherein when R1 is OH, R10 is hydrocarbyl, N-hydrocarbyl or O-hydrocarbyl;

R11 and R12 are independently selected from H and hydrocarbyl, or

- (ii) a group of formula III



Formula III

wherein R13 is hydrocarbyl and R14 is H or OH, or R13 and R14 together represent =O.

3. A use according to claim 2 wherein R1 is selected from =O, OH, O-aryl, O-acyl and O-alkyl.

4. Use according to claim 3 wherein R1 is O-CH₂-CH₂-Ph.

5


5. Use according to claim 3 wherein R1 is O-Me, O-Et or O-CH₂-cyclohexyl.

6. A use according to any of claims 2 to 5 wherein R2 is selected from H, =O, OH, O-alkylaryl, and halo.

10

7. A use according to claim 6 wherein R2 is selected from H, =O, OH, O-CH₂-Ph and F.


8. A use according to any of claims 2 to 7 wherein R3 and R4 together represent a group of formula II



Formula II

15 wherein R10, R11 and R12 are as defined in claim 2.

9. A use according to any of claims 2 to 8 wherein R3 and R4 together represent a group of formula IV




Formula IV

wherein R10, R11 and R12 are as defined in claim 2.

20


10. A use according to any of claims 2 to 9 wherein R3 and R4 together represent a group of formula V



Formula V

wherein R10, R11 and R12 are as defined in claim 2.


11. A use according to any of claims 2 to 10 wherein R3 and R4 together represent a group of formula VI



Formula VI

5 wherein R10, R11 and R12 are as defined in claim 2.

12. A use according to any one of claims 2 to 7 wherein R3 and R4 together represent a group of formula III



Formula III

wherein R13 and R14 are as defined in claim 2.

10

13. A use according to any of claims 2 to 12 wherein R10 is selected from OH and OMe.

14. A use according to any of claims 2 to 13 wherein R11 is Me.

15 15. A use according to any of claims 2 to 14 wherein R12 is Me.

16. A use according to any of claims 2 to 15 wherein R13 and R14 together represent =O or R13 is a group of the formula C(R15)(R16)(R17) wherein R15 is alkyl or a hydroxy-substitute alkyl; and

either (a) R16 is -OH or hydrocarbyl and R17 is H; or (b) R16 together with R17 is =O

17. A use according to any of claims 2 to 16 wherein R14 is H.

5 18. A use according to any of claims 2 to 17 wherein R5 is Me.

19. A use according to any of claims 2 to 18 wherein R6 is Me or H.

20. A use according to any of claims 2 to 19 wherein R7 is Me.

10


21. A use according to any of claims 2 to 20 wherein R8 is H, Me or a bond with the carbon common with the adjacent ring.

22. A use according to any of claims 2 to 21 wherein R9 is H or Me.


15

23. A use according to claim 1 or 2 wherein the compound is selected from

BLE99005




Progesterone




Progesterone-3 β ,11 β ,20 β -triol

DG326



80


DG320




24. A use according to any of claims 2 to 23 to inhibit 11 β -HSD Type 1 activity.

25. A use according to claim 24 wherein the compound is selected from


BLE99005



Progesterone



11-keto-Progesterone



5


26. A use according to any of claims 2 to 23 to inhibit 11 β -HSD Type 2 activity.

27. A use according to claim 26 wherein the compound is selected from


81

Progesterone-3 β ,11 β ,20 β -triol

DG326




DG320



28. A compound of formula I or a salt thereof

Formula I




wherein R1 is OH, O-alkyl, O-acyl or O-aryl

and R2 is selected from H, =O, OH, hydrocarbyl, oxyhydrocarbyl, and halo;

5 R5 to R9 are independently selected from H and hydrocarbyl

R3 and R4 together represent a group of formula II

Formula II



wherein R10 is selected from OH, hydrocarbyl, N-hydrocarbyl and O-hydrocarbyl, R11

and R12 are independently selected from H and hydrocarbyl,


wherein when R1 is OH, R10 is N-hydrocarbyl.

10

29. A compound claim 28 wherein R1 is O-CH₂-CH₂-Ph.

30. A compound according to claim 28 wherein R1 is O-Me, O-Et or O-CH₂-cyclohexyl.

31. A compound of formula I or a salt thereof



Formula I


wherein R1 is selected from H, alkyl, cycloalkyl, alkenyl, aryl, =O, OH, O-alkyl, O-acyl

5 and O-aryl; and

R2 is oxyhydrocarbyl

R5 to R9 are independently selected from H and hydrocarbyl

R3 and R4 together represent a group of formula III



Formula II

wherein R13 is hydrocarbyl and R14 is H or OH, or R13 and R14 together represent =O.

10

32. A compound according to claim 31 wherein R2 is O-CH₂-Ph.

33. A pharmaceutical composition comprising the compound according to any of claims
27 to 32 optionally admixed with a pharmaceutically acceptable carrier, diluent, excipient
15 or adjuvant.

34. A compound according to any of claims 28 to 32 for use in medicine.

35. Use of a compound according to any of claims 28 to 32 or a pharmaceutical
20 composition according to claim 33 in the manufacture of a medicament to inhibit 11 β -
HSD activity.


36. Use of a compound as defined in any one of claims 1 to 32 in the manufacture of a
medicament for use in the therapy of a condition or disease associated with 11 β -HSD.

25

37. Use of a compound as defined in any one of claims 1 to 32 in the manufacture of a medicament for use in the therapy of a condition or disease associated adverse 11β -HSD levels.

1/11


Protein Calibration curve: Bradford et al.



Graph 1, the amount of protein per μL of rat liver and rat kidney

Figure 1


2/11



Graph 2, enzyme concentration and time-dependency course, E to F, in rat liver 11
 β -HSD type 1 activity

Figure 2


3/11



Graph 3, enzyme concentration and time-dependency course, F to E, in rat kidney, 11 β -HSD type 2 activity

Figure 3

4/11




Graph 4, the effect of different inhibitors on the conversion E to F in rat liver, 11 β -HSD type 1.

A

Figure 4


5/11



Graph 5, the effect of different inhibitors on the conversion E to F in rat liver, 11 β -HSD type 1

Figure 5


6/11



Graph 6, the effect of different inhibitors on the conversion E to F in rat liver, 11 β -HSD type 1

Figure 6


7/11



Graph 7, the effect of different inhibitors on the conversion F to E in rat kidney, 11 β -HSD type 2

Figure 7


8/11



Graph 8, the effect of different inhibitors on the conversion F to E in rat kidney, 11 β -HSD type 2

Figure 8


9/11



Graph 9, the effect of different inhibitors on the conversion F to E in rat kidney, 11 β -HSD type 2

Figure 9

10/11




Graph 10, dose response curve of the most potent 11 β -HSD type 1 inhibitors, E to F in rat liver

Figure 10

11/11

Dose response curve F==>E in rat kidney, 11B-HSD



Graph 11, dose response curve of two potent 11 β-HSD type 2 inhibitors, F to E in rat kidney

Figure 11

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.